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ABSTRACT OF DISSERTATION

END-OF-LIFE DECISION-MAKING IN PATIENTS WITH A CARDIAC DEVICE

Heart failure (HF) is one of the top causes of mortality in the United States and
globally. In order to combat the high mortality rates of this disease, medical technology,
including internal cardioverter defibrillators (ICD) and left ventricular assist devices
(LVAD), have become one of the most common treatments. Over the past 10 years the
utilization of these cardiac devices has increased exponentially, which has created a new
phenomenon of how we discuss death with patients who have one of these devices. The
purpose of this dissertation is to increase understanding of the end-of-life decision
making processes and current experiences that patients with a cardiac device are having.
This dissertation includes four original manuscripts that focus on patients with a
cardiac device and their experiences with decision-making at the end-of-life. The first
paper is a data-based paper that examines experiences of patients with an ICD and what
factors are associated with having a conversation with their providers about end-of-life.
The second paper is an integrative review of the literature regarding what is currently
known about end-of-life with an LVAD. The third paper is a psychometric evaluation of
the Control Attitudes Scale-Revised (CAS-R) for patients with an LVAD. The fourth
paper is a data-based manuscript that looks at patients with an LVAD and their attitudes
and experiences with end-of-life conversations with providers and next-of-kin and the
impact of cognition on these attitudes and experiences. The findings of this dissertation
will hopefully inform providers of patients with cardiac devices about their patients endof-life decision making processes. It will also demonstrate the gaps that are currently in
practice, and ideally be able expand on how to assist patients and providers on improving
communication about end-of-life decision making.
KEYWORDS: end-of-life, LVAD, ICD, decision-making, heart failure, perceived control
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CHAPTER 1. INTRODUCTION
Heart disease continues to be the leading cause of death in the United States,
accounting for 23% of all deaths, and killing more than 630,000 people in 2016.1 By the
year 2030, it is estimated that 44% of American adults will have some type of
cardiovascular disease.2 Cardiovascular disease is also the leading killer globally,
estimated to have been the primary cause of death for over 17.3 million people in 2013.2
One of the deadliest types of cardiovascular disease is cardiomyopathy, also referred to as
heart failure (HF).
In the United States, one in eight deaths is attributed to HF.3 In 2012, the total
economic burden of HF was $30.7 billion, and by 2030 it is projected that this burden
will increase by 127%.3 Despite these staggering statistics, there have been improvements
in both 1-year and 5-year survival rates. This is primarily attributed to improvement in
guideline-directed medical therapy.1
Several notable advances in HF medical therapy over the last decade have been
linked to longer survival, including improved drug therapy, coronary revascularization
therapies, and advanced medical devices, including implantable cardioverter defibrillators
(ICD) and left ventricular assist devices (LVAD).4 Implantable cardioverter defibrillator
and LVAD treatment are estimated to have saved hundreds of thousands of lives since
their development.2
An ICD is a palm sized internal device that senses heart rhythms and can
electrically convert an inappropriate rhythm to normal sinus rhythm. The primary
indication for ICD therapy is to prevent sudden cardiac death in those who are high risk
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for abnormal life-threatening rhythms, such as those with advanced heart failure, or after
a myocardial infarction.5 Compared to optimized drug therapy, implantation of an ICD
decreased mortality of sudden cardiac death by almost 30%.6 It is estimated that there are
over 1.7 million Americans eligible for ICD treatment and over 12,000 lives are saved
each year due to ICD therapy.7,8
An LVAD is a mechanical pump that functions as the patient’s left ventricle. Left
ventricular assist device therapy is targeted at patients with advanced heart failure, who
have exhausted all other guideline-directed therapy and can either no longer wait for a
heart transplant due to HF severity, or are not a candidate for heart transplantation. The
first LVAD was developed in 1994 for in-hospital use only and had extremely high
mortality rates.9 The device that is most similar to what we use today, the HeartMate II,
was approved in the mid 2000’s with the well-known REMATCH trial.10 Data from this
randomized clinical trial demonstrated that LVAD therapy was superior to optimized
medical management for patients with advanced HF; LVAD therapy increased survival
for patients and also demonstrated an improved quality of life.11 In the early postREMATCH era before 2009, there were less than 500 people with an LVAD. As of 2016,
over 17,000 patients have received an LVAD.12,13
Although it is known that ICD and LVAD therapies save lives, it is inevitable that
most of these patients will face death with the device in place. Implantable cardioverter
defibrillator and LVAD devices, in the majority of cases, do not reverse HF or its effects
on the human body, therefore, patients with these devices need information and guidance
on how to incorporate their device into end-of-life planning.
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Over the past several years professional organizations have developed guidance
for communicating with patients who have an ICD or LVAD in relation to the end-oflife. For providers of patients with an ICD, guidelines from the Heart Rhythm Society, in
conjunction with other professional organizations, state that providers need to advise
patients, prior to ICD implantation, about the potential for deactivation .14 For providers
of patients with an LVAD, the Centers for Medicaid and Medicare Services mandate that
a palliative care team must be involved in the care of LVAD patients, to ensure that goals
of care are discussed, however, the guidelines are vague and do not explicitly state that
deactivation of the LVAD or end-of-life be included in these discussions.15 Other
professional organizations, such as the International Institute for Heart and Lung
Transplantation, urge providers to incorporate end-of-life discussions into the care of
patients with an LVAD, however, these guidelines are also vague and do not directly
address deactivation or involvement of palliative care teams throughout LVAD therapy.16
Despite guidelines from professional organizations, patients with a cardiac device,
their caregivers, and their health care providers do not seem to be equipped to deal with
end-of-life situations that may arise with these devices. Results from numerous studies of
patients with an ICD have shown that many experience inappropriate and unnecessary
shocks toward the end-of-life, even within minutes before death.17-19 Even though
professional guidelines urge providers of patients with an ICD to initiate discussions
about ICD deactivation, researchers have demonstrated that these types of conversations
happen infrequently, if at all, with patients and their families.19-21 These gaps in care can
leave patients and their families in frustrating and confusing situations in a time that is
already very difficult.
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There has been very little research about end-of-life experiences or deactivation
of the LVAD device. This is most likely related to the relative newness of the technology.
Several editorials have been written regarding the lack of shared decision-making in the
end-of-life processes associated with LVAD deactivation. These authors proposed that
this problem may be related to a lack of understanding of the ethical permissibility of
deactivation.22-25 In 3 qualitative studies examining LVAD patients and their caregivers, a
common theme related to end-of-life with an LVAD emerged: confusion. The
participants in these studies consistently voiced a lack of understanding of end-of-life
processes with an LVAD, difficulty receiving information from providers about
deactivation, and questions of whether it is ethical to turn the device off at all.26-28
Providers of patients with LVADs also seem to have similar uncertainty about end-of-life
with an LVAD. In a web-based survey of different specialties who take care of patients
with LVADs, there were vastly different opinions regarding whether deactivation of the
LVAD is considered active euthanasia or physician assisted suicide, as well as confusion
how to integrate hospice and palliative medicine for patients who wish to deactivate their
LVAD towards the end of their lives.29-31
Therefore, the purpose of this dissertation was to examine patient attitudes and
experiences related to end-of-life conversations involving their LVAD or ICD and factors
involved in end-of-life decision making. The chapters of this dissertation demonstrate the
development of my initial program of research. First, I did a secondary data analysis of a
national cohort study of patients with an ICD to determine the factors associated with
having a conversation about end-of-life with their providers. Second, I conducted an
integrative review of the literature to examine what is currently known about end-of-life
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with an LVAD related to providers’, patients’, and caregivers’ experiences of end-of-life
with this device. Third, is an analysis of the psychometric properties of the Control
Attitudes Scale-Revised in a population of patients with an LVAD. Last, I did an
observational study of a cohort of patients with an LVAD and an exploration of their
attitudes and experiences related to end-of-life decision-making and pump exchange of
patients with an LVAD and the impact of cognition on these attitudes and experiences.
1.1 Summary of Subsequent Chapters
In order to understand of predictors of end-of-life discussions and decision
making in patients with an ICD, Chapter Two presents a secondary data analysis of a
national cohort study comparing experiences, attitudes, and knowledge about the ICD at
the end-of-life between ICD recipients with and without HF. A total of 3,067 ICD
recipients participated, and 52% of the cohort had HF. End-of-life experiences, attitudes,
and knowledge were measured using an end-of-life questionnaire, demographic and
medical history information were self-reported, and information regarding ICD indication
and shock history were gathered using a national Swedish ICD registry. Experiences,
attitudes and knowledge were compared between the HF and non-HF groups and a
logistic regression analysis was conducted to identify significant predictors of having a
discussion with a health-care provider about end-of-life scenarios. The questionnaire and
study design from this analysis were used to guide the study conducted and described in
Chapter Five of this dissertation.
For a more comprehensive understanding of what the LVAD population
experiences towards the end-of-life, Chapter Three is an integrative review of the
literature regarding processes and content of end-of-life discussions, and end-of-life
5

experiences of individuals, families, and health-care providers of patients with an LVAD.
Several electronic databases were searched from earliest available through November
2018, with keywords including ‘LVAD’ and ‘end-of-life’. Articles were included if they
met the following criteria: were research studies that focused on the perspective about
end-of-life of provider, caregiver, or patient with an LVAD, focused on adults 18 and
older, and were published in English. Articles were excluded if the primary research
focus was testing palliative care interventions in patients with an LVAD. Six articles met
the inclusion criteria and were included in the integrative review. Three focused on
provider knowledge and opinions of end-of-life for patients with an LVAD and three
studies examined patient and caregiver experiences related to end-of-life processes
associated with the LVAD.
To ensure there is a validated instrument to measure perceived control, Chapter
Four reports on the psychometric properties of the Control Attitudes Scale-Revise (CASR) in an LVAD population. The CAS-R is a measure of perceived control, which is a
variable that is often targeted in interventions to improve quality of life because of the
ability to modify and improve perceived control. This was a secondary data analysis of
89 LVAD patients from a larger prospective research study described elsewhere.32 The
purpose of this study was to evaluate the internal consistency reliability and convergent
validity of the CAS-R in an LVAD population. Reliability was assessed with Cronbach’s
alpha, inter-item and item-total correlations to assess for homogeneity of the scale.
Convergent validity was assessed using factor analysis and hypothesis testing.
Last, in culmination of the research from the prior chapters, Chapter Five presents
the findings of cross-sectional, correlational study of 30 patients with an LVAD focused
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on end-of-life attitudes and experiences and the impact of cognition on those attitudes
and experiences. Patients were eligible to participate if they had an LVAD device for the
treatment of end-stage HF, had the device for at least 30 days, were able to complete a
three-question cognitive assessment, and were able to speak and write English.
Participants were excluded if they were less than 18 years of age or resided in an
extended care nursing facility. Participants completed a cognitive screening tool and an
end-of-life questionnaire focused on experiences related to end-of-life decision making
and attitudes towards end-of-life decision making and pump exchanges.
Chapter Six is an integrated discussion synthesizing the prior chapters of this
dissertation and discusses how these studies contribute and advance what is already
known regarding end-of-life decision making and care for patients with a cardiac device.
There are also recommendations for future research and practice regarding end-of-life
decision making in these populations.

CHAPTER 2. SHARED DECISION-MAKING ABOUT END-OF-LIFE CARE
SCENARIOS COMPARED AMONG IMPLANTABLE CARDIOVERTER
DEFIBRILLATOR PATIENTS WITH AND WITHOUT HEART FAILURE: A
NATIONAL COHORT STUDY
2.1 Introduction
Heart failure (HF) affects over 6.5 million people in the US every year, and the
trajectory of a patient’s life is shortened once a HF diagnosis has been made.1 Over 42%
of people diagnosed with HF will die in less than five years after diagnosis.1 Many of
these HF patients require the placement of an implantable cardioverter defibrillator (ICD)
to prevent sudden cardiac death, a major cause of death in HF. There are about 800,000
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patients with HF who have an ICD in the US, and an additional 800,000 HF patients who
qualify for ICD treatment but do not have one.2
Approximately 30% of ICD recipients experience a shock in the minutes before
death.3 Many of these shocks are not in the context of sudden cardiac death, but in the
context of death from a terminal illness such as cancer.4 According to guidelines
developed by the Heart Rhythm Society, in conjunction with multiple professional
organizations, providers are advised to discuss the potential for deactivation of ICDs in
certain situations such as a terminal illness, prior to implantation of the ICD.5 Despite
these guidelines, in multiple studies of patients with and without HF, these discussions
did not occur, or occurred very infrequently.3,6,7 One of the consequences of failure to
have end-of-life (EOL) discussions throughout the illness trajectory is potentially
decreased quality of life (and quality of death experience) at the EOL. Thus, the purpose
of this study was to compare experiences, attitudes and knowledge about the ICD at EOL
between ICD recipients with and without HF to determine how well patients with HF
could participate in EOL decisions. We hypothesized that given the poor prognosis in HF
compared to other patients with an ICD, clinicians would have had discussions about the
ICD at the EOL with HF patients more commonly.
2.2 Methods
2.2.1 Sample, Study Design, and Data Collection
This study was a cross-sectional and correlational design. All data were selfreported and participants were recruited from the national database of all Swedish ICD
and pacemaker recipients. This registry has been active since 1989 and included 5,535
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adult ICD recipients as of 2012. All ICD recipients were sent an invitation to participate
in the study, and if a signed consent form was returned, a questionnaire was mailed. If the
questionnaire was not returned in two weeks, one reminder was sent out. This study was
sanctioned by the Regional Ethics Committee for Human Research at the University of
Linköping, Sweden and followed the principles outlined by the Declaration of Helsinki.
2.2.2 Demographic and Clinical data
Demographic data and information on participants’ co-morbidities, including HF,
medications, and ICD shock history were collected using self-report. Data regarding
indications for ICD placement, implantation and generator replacement history, and
device types (ICD versus ICD with a cardiac resynchronization pacemaker/CRT-D) were
collected using the Swedish ICD and Pacemaker Registry.
2.2.3 End-of-life information
The questionnaire used to collect data on EOL knowledge, perceptions, and
attitudes is titled “Experiences, Attitudes, and Knowledge of End-of-Life Issues in ICD
Patients” (EOL-ICD). It is a self-rated questionnaire that includes three domains related
to EOL in patients with an ICD. The domains included are, experiences (10 items),
attitudes (18 items), and knowledge (11 items). This questionnaire was developed and
tested for construct validity, content, homogeneity and reliability in a Swedish setting;
these properties were considered sufficient after evaluation.8 In the current sample of
2,566 participants with an ICD the Cronbach’s alpha was 0.719.
The experience domain included items about discussions with either providers or
family about EOL care and experiences. An example of an item in this domain was, “I
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have told my next of kin (either in writing or orally) my wishes regarding the defibrillator
shocks in my ICD, if I become seriously ill with some fatal disease”. The knowledge
domain was concerned with the patient knowledge about ICD deactivation. An example
of a question in this domain was, “An ICD always gives defibrillator shocks in
connection with end-of-life”. Lastly, the attitudes domain included items about the
patient’s feelings, emotions, and attitudes about potential discussions related to ICD
deactivation and future events related to the ICD. An example in this domain was “I want
to have the defibrillator shocks in my ICD even if I’m dying of cancer or another serious
disease”. Patients listed their answers to these questions as “agree/don’t agree”,
“true/false”, “I don’t know”, “yes/no”, or “no opinion”.
2.2.4 Implantable Cardioverter Defibrillator Concerns Scale
The Internal Defibrillator Concerns Scale (ICDC) short version is an 8-item scale
that assesses patient related concerns regarding the ICD. This instrument helps identify
patients who are at risk for adverse outcomes related to the ICD by identifying how
worried various aspects related to the ICD the patient is concerned with.9,10 Patients rate
the items on a 5-point Likert scale with 0 being not worried at all, to 4 being very much
worried.10 The items are scored and totaled with a range from 0-32, with 0 being not
worried at all about the ICD, to 32 being extremely concerned about the ICD.10 This has
been shown to have excellent reliability and validity in various ICD populations.9,10 In the
current sample of 3,003 participants with an ICD, the Cronbach’s alpha was 0.944, also
indicating excellent reliability. The median total score from the sample was used as a cutpoint for low ICD concerns, and higher ICD level of concerns.
2.2.5 Hospital Anxiety and Depression Scale
10

The Hospital Anxiety and Depression Scale (HADS) is a brief self-report
instrument used to detect symptoms of anxiety and depression in multiple
populations..11,12 It is divided into anxiety and depressive subscales that have also been
validated and have demonstrated good reliability.11,13 The anxiety and depression
subscales each have 7 items, scored on a 4-point Likert scale; each item score on the
subscale are summed and can have a total score from 0-21.11 Based on clinical
presentations of generalized anxiety and depressive disorders, cut points of greater than
or equal to 8 on the HADS anxiety and depression subscales were considered acceptable
cut-points.11
2.2.6 Data analysis
For data analysis, we used SPSS version 24. We used means ± standard
deviations, and frequencies and proportions to describe patient characteristics.
Comparison of demographic and clinical characteristics, and experiences, attitudes, and
knowledge between HF and non-HF groups was accomplished using X2 and independent
t-tests. Hierarchal binary logistic regression was used to determine predictors of whether
or not participants had deactivation discussions with their providers. The assumptions for
logistic regression were tested and were not violated. The outcome was participant
responses to the question “Have you discussed what turning off shocks/deactivating the
ICD involves with a doctor?” Four blocks were entered, in block one sociodemographic
information was entered, block two included co-morbidities, block three included ICD
related information, and block four was anxiety and depression. A probability values of
less than 0.05 was considered to be statistically significant.
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2.3 Results
2.3.1 Sample Characteristics
There was a total of 3,067 participants who responded to the questionnaire and
were included in the analysis (Table 2.1). Of these, 1,461 (47%) stated they had HF. The
average age of the participants with HF were older than those without HF (p-value
<0.001). The HF cohort was more likely to have higher levels of depressive and anxiety
symptoms compared with the non-HF (p-value <0.001). The HF cohort was more likely
to suffer from comorbidities including history of myocardial infarction, diabetes and
history of stroke (p-values all less than 0.001). It was also evident that those participants
without HF were more likely to have experienced a shock than those with HF (p-value
0.012), and those without HF were more likely to have received an ICD related to
secondary prevention compared to those with HF (p-value <0.001). See Table 2.1.
2.3.2 EOL-ICDQ Results
To determine whether there were differences in understanding of EOL situations
between those with and without HF, we compared responses to the EOL-ICD
questionnaire between HF and non-HF cohorts (Table 2.2). There was little variation
between the cohorts in the majority of the domains indicating that in general, they had the
same attitudes and equivalent knowledge about ICD deactivation, EOL care, and patient
control. However, some differences were observed between the cohorts in the
experiences domain (Table 2.2). Those without HF were more likely to have discussed
battery replacement with their provider and next-of-kin than those with HF. Additionally,
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a larger percentage of those without HF had more thoughts and questions concerning
EOL compared to those with HF.
Tables 2.3A and 2.3B show the results of the attitudes portion of the EOL-ICDQ.
Among these 18 questions, there were only significant differences between cohorts for
two questions. Question 13, would you want the ICD battery replaced, even at an
advanced age. A higher percentage of patients with HF replied “yes” than those without
HF. The other difference in the attitudes portion of the questionnaire was regarding the
desire for the doctor to decide if ICD shocks should be turned off at the EOL. More
patients with HF replied “yes” they would prefer this option compared to those without
HF.
Last, in Table 2.4, the percentage of each cohort that got the questions correct, as
well as the total knowledge score of the EOL-ICDQ are presented. While there was no
difference in the overall scores between the cohorts, there were three questions that the
non-HF cohort picked the correct response more than the HF cohort. Question 12 was the
only question that the HF cohort picked the correct response more frequently that the
non-HF cohort.
2.3.3 Hierarchal Logistic Regression Results
Because we found that HF was not related to more comprehensive understanding
of EOL with an ICD, we sought to understand what predictors were associated with
having discussions with providers regarding EOL with an ICD. To determine these
predictors a hierarchal logistic regression was performed. Block one with age, gender,
education, and living alone was non-significant. Block two was significant with HF, atrial
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fibrillation, and history of myocardial infarction were entered in the model (p =0.003);
the Hosmer and Lemeshow goodness-of-fit coefficient was 0.296, indicating acceptable
model fit. In block three, ICD variables were entered, including whether patients had a
high level of ICD concerns, whether they had been shocked in the past, and whether their
ICD was implanted for secondary prevention. This model block had a p-value of less than
0.001 and the Hosmer and Lemeshow test showed a coefficient of 0.601, indicating good
model fit. In block four, whether or not patients had symptoms of anxiety and depression
were added to the model. The model remained significant with highest Hosmer and
Lemeshow coefficient of 0.958, indicating good model fit. In the final model with all
potential predictors, the significant predictors of having a discussion with the provider
were having high levels of ICD concerns (p<0.01), having had a shock in the past
(p<0.001), and having a high level of anxiety (p=0.027; Table 2.5).
2.4 Discussion
Our hypothesis that participants with HF would have a better understanding of
EOL with an ICD because of their shortened life expectancy was not supported.1 Results
from the EOL-ICDQ indicated that participants with and without HF had similar
responses. However, we also saw that the participants with HF had more symptoms of
anxiety and depression compared to those without. Despite the shortened life expectancy,
and higher levels of symptoms of anxiety and depression, those with HF did not want to
initiate discussions regarding EOL any more frequently than those without.
Our results are congruent with other research in the ICD and HF communities. It
has been shown that patients are reluctant to have their ICD deactivated at the EOL,
despite recommendations from providers.14-16 It is also uncommon to have information
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regarding ICD deactivation in an advanced directive or living will.17 This is consistent
with our findings which demonstrate that over 40% state they never wanted to have a
discussion about deactivation of the ICD at the EOL with their provider, and only 11% of
those with HF had ever had any EOL conversation with their next-of-kin. It also
important to note that both those with and without HF had poor knowledge regarding
what EOL with an ICD entailed. In the same cohort of Swedish participants, only 3% of
participants scored correctly on all the knowledge questions and over 25% were
considered to have inadequate knowledge.18 This prior study also demonstrated that those
with poor knowledge were more likely to have a stressful and potentially painful EOL.18
Poor knowledge and lack of desire to have a discussion regarding EOL with an ICD are
strong barriers to shared decision making regarding the EOL.
Shared decision making, an established concept, is becoming a more crucial
component of modern healthcare. This concept is succinctly described as “helping
patients understand the importance of their values and preferences in making decisions
that are the best for them”.19 It is ideally used in individualizing the plan of care for
patients and ensuring that they are receiving medical treatment that is cohesive with
patients’ goals for life, or in our scenario, the goals for EOL care. Initially we
hypothesized that those with HF would have a higher level of shared decision making
because of their shortened life expectancy and complications of their chronic disease,
however, through our analysis we saw that in general, their experiences and preferences
were identical to those without HF.
We found factors associated with having a deactivation discussion were primarily
ICD related, including a history of an ICD shock and having high levels of ICD concerns.
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The other factor was anxiety symptom, which has a significant relationship with shared
decision making and how patients interact with their providers.20 These associations may
indicate when there is a potential for interventions regarding education on EOL scenarios.
If we know patients are more open to having conversations about EOL after they have
been shocked, or have high levels of anxiety and concerns about their ICD, we can
prompt these types of discussions and ideally increase patients’ awareness about how an
ICD can impact EOL. In a recent systematic review of the literature, a key point of shared
decision making revolved around whether a patient is willing to take action.21 In this
sample we saw that when patients had received an ICD shock, or when they had levels of
concern about their ICD, they were more willing to take action regarding creating a plan
for their EOL that included their ICD.
By having a more thorough understanding of which patients are willing to
participate in EOL education, we may be able to address misconceptions and improve
quality of death in this population. Having a HF diagnosis may not be sufficient to
overcome the barrier of not wanting to discuss EOL with providers, but other clinical
scenarios, such as being shocked or having high levels of symptoms of anxiety, do
provide this kind of opportunity, and as providers it is crucial to capture them at these
times. Additionally, shared-decision making regarding EOL can help alleviate some of
the problems that frequently occur at the end of life, such as being shocked
inappropriately, or forcing the next-of-kin to make a decision about deactivation when
they have never had this type of discussion with their loved one.
Moving forward it will be important to understand how to educate patients with
HF about EOL scenarios with an ICD. Despite the guidelines that suggest providers have
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these discussions prior to implantation and regularly after implant, our study shows that
this ongoing discussion did not occur in the majority of participants. Additional studies
should focus on ways to reach patients with and without HF who are reluctant to discuss
EOL scenarios with providers ever, because we saw this was almost half of our sample.
These patients may need additional education prior to implantation to ensure they
understand the implications that cardiac devices may place on their lives and their deaths,
and make sure the care team understands their wishes.
2.5 Limitations
There were several limitations to this study, including that all the respondents
were from the same geographical location, which limits generalizability. Also, because
this information was self-reported through survey, some portions of the population may
not have been able to respond, also limiting generalizability.
2.6 Conclusions
While HF diagnosis was not associated with increased likelihood of having
discussions about EOL with a provider, several other factors were identified, including
high ICD concern level, high levels of symptoms of anxiety, and having an ICD shock.
Future studies should focus on ways to better reach patients who are reluctant to have
discussions regarding EOL. More education and guidance is also needed for providers
regarding having discussions about EOL with patients an ICD to better improve patient
quality of life and quality of death.
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Table 2.1. Patient Characteristics and Comparison of Characteristics by Heart Failure and
Non-Heart Failure Status (N=3067)
Total

With HF

Without HF

N=3067

N=1606

N=1461

P-value

Mean ± SD or
n (%)
Mean ± SD or n (%)

Sociodemographics
Age

66 ± 12

67 0.101 10

64 ± 13

<0.001

Female

629 (21)

309 (19)

320 (22)

0.073

Living Alone

648 (21)

352 (22)

296 (20)

0.240

Education: 9 years or less

1009 (33)

533 (34)

476 (33)

0.700

Works outside the home

705 (23)

280 (18)

425 (30)

<0.001

Pensioner

2074 (68)

1162 (76)

912 (65)

<0.001

Other Employment Type

156 (5)

91 (6)

65 (5)

<0.001

Time since implant: years

5±4

4±4

5±4

<0.001

CRT-D

2346 (77)

578 (36)

139 (10)

<0.001

Etiology: cardiomyopathies

2428 (79)

1422 (90)

1006 (70)

<0.001

Myocardial Infarction

1037 (34)

677 (42)

360 (25)

<0.001
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Diabetes

612 (20)

376 (23)

236 (16)

<0.001

Hypertension

1072 (35)

581 (36)

491 (34)

0.139

Stroke

272 (9)

186 (12)

86 (6)

<0.001

Depression: >HADS 8

263 (9)

173 (11)

90 (6)

<0.001

Anxiety: >HADS 8

485 (16)

299 (19)

186 (13)

<0.001

Has received a shock

1056 (35)

519 (33)

537 (37)

0.012

Received ICD for secondary

1957 (64)

828(52)

1129(77)

<0.001

prevention
Legend: CRT-D- Cardiac resynchronization therapy-defibrillator; HADS- Hospital anxiety
and depression scale

Table 2.2: Comparison of Implantable Cardioverter Defibrillator Experiences Between
Heart Failure and Non-Heart Failure Patients
Heart

Non-Heart

Failure

Failure

n= 1606
n (%)
Question 1: Discussed Battery

636 (40)

Replacement with Doctor/Nurse, Yes
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P-Value

n=1461
n (%)

674 (47)

<0.001

Question 2: Discussed battery

468 (29)

518 (36)

<0.001

216 (14)

222 (15)

0.148

171 (11)

163 (11)

0.642

123 (8)

86 (6)

0.062

46 (3)

71 (5)

0.004

624 (39)

502 (35)

0.014

665 (42)

470 (33)

<0.001

1317 (83)

1209 (84)

0.403

1296 (82)

1233 (86)

0.003

replacement with next-of-kin, Yes
Question 3: Discussed what turning off
shocks with a doctor involves, Yes
Question 4: Discussed what turning off
shocks means with next-of-kin, Yes
Question 5: Informed next-of-kin
wishes related to defibrillator shocks if
seriously ill, Yes
Question 6: Considered asking doctor
to turn off shocks, Yes
Question 7: Discussed heart disease
development with doctor
Question 8: Discussed heart disease
development with next-of-kin
Question 9: Has a religious
faith/outlook on life, helps manage
daily life, Yes
Question 10: Often think about
questions concerning End-of-life, Yes
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Table 2.3A: Implantable Cardioverter Defibrillator Attitudes
When would you like healthcare staff to broach the question of what it involves to turn
off the defibrillation shocks in your ICD – Heart Failure vs. Non-Heart Failure
Heart Failure
n= 1606

Non-Heart

P-Value

Failure
n=1461

n (%)
n (%)
Question 1: Pt does not wish to

633 (40)

571 (40)

0.911

1326 (84)

1203 (84)

1.000

759 (49)

707 (51)

0.377

815 (52)

687 (49)

0.091

1022 (66)

916 (65)

0.644

981 (63)

889 (63)

1.000

have such conversation, Agree
Question 2: Pt will themselves
broach the question when they
feel they need to, Agree
Question 3: In connection with
ICD surgery, Agree
Question 4: If pt receives a
defibrillator shock, Agree
Question 5: If pt has repeated
defibrillator shocks, Agree
Question 6: Upon repeatedly
being hospitalized because of
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recurring heart problems,
Agree
Question 7: If pt should suffer

1007 (64)

925 (65)

0.619

670 (43)

579 (41)

0.354

1015 (65)

920 (65)

0.818

1077 (69)

966 (69)

0.691

from disease with poor
prognosis, Agree
Question 8: Routinely when pt
visits the ICD clinic
Question 9: If heart disease
deteriorates, Agree
Question 10: Towards end-oflife, during last days, Agree
Legend: Pt- patient; ICD- Implantable cardioverter defibrillator

Table 2.3B: Implantable Cardioverter Defibrillator Attitudes
“In time your general state of health or heart disease may deteriorate. Try to imagine
how you (the patient), at this moment, feel about your (the patient) ICD treatment in
the future…”
Heart Failure
n= 1606

Non-Heart
Failure n=1461
n (%)
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P- Value

n (%)
Question 11: Pt wants to have the
battery in ICD replaced even if they
never received defibrillator shocks:
Yes
1251 (80)

1130 (79)

72 (5)

69 (5)

244 (16)

229 (16)

861 (55)

773 (54)

167 (11)

162 (11)

540 (34)

491 (34)

1017 (65)

859 (60)

143 (9)

162 (11)

No
0.888

No opinion

Question 12: PT wants to have battery
replaced, even if seriously ill suffering
from another disease:
Yes
0.815

No
No opinion

Question 13: Pt wants to have battery
replaced even if reached an advanced
age:
Yes
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0.022

No

410 (26)

405 (28)

375 (24)

296 (21)

596 (38)

556 (39)

595 (38)

575 (40)

288 (18)

271 (19)

472 (30)

437 (31)

808 (52)

715 (50)

1009 (65)

923 (65)

No opinion
Question 14: Pt wants to have
defibrillator shocks even if pt dying of
cancer or other serious disease:
Yes
0.101

No
No opinion

Question 15: Pt wants to have
defibrillator shocks even if receiving
shocks daily:
0.773

Yes
No
No opinion
Question 16: Pt wishes to decide
themselves if shocks are to be turned
off when finding themselves at end-oflife
Yes
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0.966

No

98 (6)

87 (6)

No opinion

458 (29)

412 (29)

602 (39)

475 (34)

516 (33)

500 (35)

442 (28)

442 (31)

513 (33)

458 (32)

530 (34)

472 (33)

513 (33)

486 (34)

Question 17: Pt wants the doctor to
decide if the shocks be turned off at the
end-of-life:
Yes
0.015

No
No opinion

Question 18: Pt wants next-of-kin to
decide if the shocks be turned off when
pt at the end-of-life:
Yes
0.738

No
No opinion

Table 2.4: Implantable Cardioverter Defibrillator (ICD) Knowledge Questions
Each statement had a correct answer, participants could choose either true or false
based on their own knowledge about their ICD.
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Heart Failure

Non-Heart Failure

P-Value

n=1371

n= 1533

n (%)

n (%)
Question 1: Correct

1161 (74)

1100 (77)

0.038

Question 2: Correct

1074 (68)

1036 (73)

0.009

Question 3: Correct

1326 (84)

1224 (86)

0.218

Question 4: Correct

982 (63)

914 (64)

0.343

Question 5: Correct

1147 (73)

1051 (74)

0.508

Question 7: Correct

671 (43)

600 (42)

0.795

Question 8: Correct

1107 (70)

990 (70)

0.689

Question 9: Correct

570 (36)

587 (41)

0.005

Question 10: Correct

451 (29)

433 (31)

0.316

Question 11: Correct

1015 (65)

941 (66)

0.420

Question 12: Correct

774 (49)

632 (44)

0.007

Total Score (mean ±

6.6±2.7

6.7±2.8

0.251

SD)
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Table 2.5: Independent predictors of having an end-of-life discussion with a provider; N=
2,840
Odds Ratio

95% Confidence

B

SE

P

Interval
Age

0.994

0.984-1.003

-0.006

0.005

0.200

Gender: Female

1.056

0.808-1.380

0.054

0.137

0.691

Living Alone

1.079

0.832-1.398

0.076

0.132

0.567

More than 9

0.893

0.705-1.131

-0.113

0.120

0.347

0.895

0.712-1.127

-0.111

0.117

0.346

1.206

0.962-1.512

0.187

0.115

0.104

History of MI

0.797

0.625-1.016

-0.227

0.124

0.067

High Level of

1.526

1.217-1.915

0.423

0.116

<0.001

years of
education
Has heart
failure
Has atrial
fibrillation

ICD concerns
(score on ICDC
>7)
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Having had an

2.049

1.637-2.564

0.717

0.114

<0.001

1.147

0.897-1.467

0.137

0.126

0.275

1.411

1.040-1.915

0.344

0.156

0.027

1.038

0.701-1.537

0.038

0.200

0.851

ICD shock in
the past
ICD for
secondary
prevention
High anxiety
symptoms
(HADS score
>8)
High depressive
symptoms
(HADS score
>8)
Legend: Overall model p-value <0.001; ICD: internal cardioverter defibrillator; ICDC:
internal cardioverter defibrillator concerns scale; HADS: hospital anxiety and depression
scale; MI: myocardial infarction
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CHAPTER 3. LEFT VENTRICULAR ASSIST DEVICES AT THE END-OF-LIFE: AN
INTEGRATIVE REVIEW
3.1 Introduction
Heart failure (HF) is a growing epidemic in the United States. By the year 2030
over 8 million Americans will have a HF diagnosis.1 Despite the increasing prevalence of
the condition, and improved guideline directed medical therapy, the five-year mortality
rate of HF is still extremely high at 80%. 2 Since the Food and Drug Administration first
approved left ventricular assist devices (LVADs) for use as bridge to heart transplantation
in 1994, the science and rapid utilization of these devices has grown exponentially.3
Between 2008 and 2016, over 17,000 LVADs were implanted in the United States and
that number will continue to grow due to the lack of available donor hearts and the
growing number of Americans with HF.4 While scientific advancements such as LVADs
do increase life expectancy compared to optimized medical management, the mortality
rate at one year is 19%.4,5 While many patients experience improvements in their quality
of life after implantation, around 20% of LVAD patients experience a poorer quality of
life post-implant.6
Despite the life-prolonging capacity of LVADs, there are significant risks
associated with the device that can ultimately lead to death. The most common causes of
death in the LVAD population are neurologic complications, primarily stroke, which is
the primary cause of death in 20% of patients. Multi-system organ failure is responsible
for death in 14% of LVAD patients, and major infection is the cause of death in 7.6% of
patients.7 Investigators have also demonstrated that compared to other chronic illnesses,
patients with an LVAD overwhelmingly die in an intensive care unit rather than in the

comfort of their own home or other location of their choice.8,9 Because of these factors, it
is critical that patients who have been implanted with an LVAD, their healthcare
providers, and their next-of-kin discuss end-of-life situations and are prepared for when
the inevitable occurs.
Professional organizations that advise providers who care for patients with an
LVAD have acknowledged that end-of-life is an important area and have created
guidelines for providers. The Centers for Medicaid and Medicare Services have mandated
that a palliative care team be involved in the care of LVAD patients to ensure that goals
of care be discussed, but these guidelines are vague and do not discuss the extent to
which palliative care must be involved, the composition of the palliative care team, or if
end-of-life discussions must occur.10 The International Society for Heart and Lung
Transplantation also recommends that a palliative care team be involved prior to LVAD
implantation to help facilitate discussion of end-of-life and establish an advanced
directive; however, there is no recommendation about the continuation of palliative care
involvement, or what content should be discussed in these consultations other than
advanced directives.11
Authors of several editorials have also discussed end-of-life with an LVAD and
determined that there is a strong need for increased shared decision-making among
LVAD patients, caregivers, and their providers.12,13 These experts proposed that a lack of
shared-decision-making has created confusion for patients, families, and clinicians
involved in end-of-life discussions.12,13 Phan et al., discussed how death can be hard to
determine in patients with an LVAD due to the technical aspects of the device, which can
still be functioning despite neurological or pulmonary system failure.14 This difficulty can
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cause extreme confusion and frustration, especially for families who are often deemed the
decision-maker at the EOL.14 In an attempt to deliver a consensus on the ethical
permissibility of LVAD deactivation, Rady and Verheijide evaluated the legality of
deactivation. They determined after consultation with physicians and legal
representatives, that in a new onset lethal condition only, such as new diagnosis of
cancer, it is ethically permissible to deactivate an LVAD.15
High mortality rates, vague guidelines about end-of-life care, and a demand of
further understanding by providers seen in published editorials, clearly demonstrate a
need for a more thorough understanding about end-of-life care for patients with an
LVAD. Despite a few pilot studies that examined the effectiveness of preparedness
planning for dyads including patients with an LVAD and their caregivers,16-18 there is no
established understanding of end-of-life decision making in the literature. This includes
understanding current practice with the various participants in the LVAD community
including providers/clinicians, caregivers, and patients with an LVAD. Therefore, the
purpose of this integrative review was to systematically evaluate research studies that
focused on the process and content of end-of-life discussions, attitudes towards these
discussions, and end-of-life experiences of individuals, families, and health care
providers of patients with an LVAD.
3.2 Methods
3.2.1 Search Strategies
We performed a literature search of the PubMed, PsychINFO, and CINAHL
databases. The keywords searched included: “LVAD” or “left ventricular assist device”,
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and “end of life”. Secondary search terms utilized were “provider”, “caregiver”,
“physician”, and “coordinator”. Databases were searched from earliest available to
November 1st, 2018; no time restriction was used as the use of the LVAD is a recent
innovation. References from the thirteen articles selected for full analysis for inclusion
were evaluated, but revealed no new studies for review.
3.2.2 Inclusion and Exclusion Criteria
Studies were included in this review when they: 1) were research studies that
focused on the perspective about end-of-life of provider, caregiver, or patient with an
LVAD 2) focused on adults (³18 or older); and 3) were published in English. Articles
were excluded when the primary research focus was testing palliative care interventions
for preparedness planning.
3.2.3 Quality Assessment
Multiple study designs were included in this integrative review; thus, an
instrument designed to assess multiple types of studies was needed. Pluye et al,19
developed an instrument that incorporates multiple types of assessments for the various
study types, including mixed-methods, quantitative, and qualitative studies. This
instrument is known as the Mixed Methods Appraisal Tool (MMAT), version 2018.20 The
MMAT has two screening questions that apply to each type of study, and then depending
on the specific study type, there is a range of 3-5 items appraising the quality of the
various studies. The developers of this instrument suggest not scoring the quality, but
rather assessing whether each study has addressed the various appraisal items with an
answer of ‘yes’, ‘no’, or ‘cannot tell’, and an explanation for the choice by the reviewer.
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The authors then suggest judging over-all quality by reviewing the explanations of the
criterion and comparing results of the common studies to make an over-all conclusion.20
3.3 Results
The initial search strategy resulted in 68 articles, and after abstract review and
application of inclusion and exclusion criteria, 13 studies were evaluated for full review
(see Figure 3.1 for flow-chart). After full review, six studies were included in the
integrative review based on inclusion and exclusion criteria. Three were qualitative
studies focused on end-of-life discussions and experiences of caregivers and patients with
an LVAD, two quantitative studies focused on provider opinions about LVAD
deactivation or withdrawal of an LVAD, and one mixed-methods study focused on
provider opinions of LVAD withdrawal and deactivation.
The qualitative studies included in this review used grounded theory and
qualitative descriptive methodology. Investigators for all studies used convenience
sampling, and for two out of the three, investigators used open-ended, semi-structured
interviews;21,22 researchers for the remaining study used a structured, three-question openended interview style.23 All interviews focused on patients and caregivers experiences
with end-of-life discussions, or the experiences of caregivers related to the processes
associated with end-of-life with an LVAD. The qualitative studies included in this review
had a total of 70 caregivers and 39 patients with an LVAD. The caregivers in these
studies were predominantly female, white, and either married or cohabitating partners of
patients with an LVAD. The 39 patients with an LVAD interviewed in these qualitative
analyses were predominantly white, males, and over 50 years of age; this is consistent
with the LVAD population as a whole.7
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Investigators for the two quantitative studies and the mixed-methods study, used
cross-sectional designs. The investigators for the two quantitative studies, and the mixedmethod study all used a 41-item web-based survey entitled, “Characterization of
Physician Attitudes Towards Deactivation of Left Ventricular Assist Devices as
Destination Therapy at Life’s End”, which focused on attitudes and practices of clinicians
who cared for patients with an LVAD at the end-of-life. In addition to the web-based
survey, investigators for the mixed-methods study used a convergent parallel study
design, indicating that the researchers collected the quantitative and qualitative data at the
same time, where they asked the participants to elaborate on why they chose certain
answers.24 In all three studies, a total of 865 clinicians who provided care to patients with
an LVAD completed the web-based survey, most were physicians, male, and in the
cardiology field.24-26
3.3.1 Qualitative Studies about End-of-Life
The qualitative evaluation of patient and caregiver end-of-life experiences or
discussions were examined in three studies,21-23 with similar themes emerging in all.
Caregivers of patients with an LVAD were interviewed in all three studies; however, in
one study caregivers as well as patients were interviewed.22 Investigators for only one of
the studies recruited participants at multiple institutions,22 while investigators for the
other two studies recruited participants from a single institution.21,23
3.3.1.1 Difficulty Receiving Information
The most common theme identified by investigators in all three qualitative
analyses was expressed by both patients and caregivers and was the difficulty in
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receiving information from healthcare providers about the end-of-life experience. One
participant stated, “In fact, I did ask them one time and I didn’t get an answer…”
regarding what the end-of-life with an LVAD would be like.22 There was a strong desire
from caregivers to understand what would occur at the end-of-life, and unfortunately
many providers, especially those with hospice and palliative care, could not answer their
questions, because the providers lacked the knowledge to respond.21,23 The inability of
providers to inform patients and their caregivers about what happens at the end-of-life led
to confusion and frustration for patients and their caregivers about end-of-life
experiences. Thus, investigators concluded that patients had difficulty getting the
information because providers did not have adequate knowledge or experience to be able
to answer their questions. The statement below is an example of this theme:
“They don’t know what they’re gonna do... Do you leave the mechanism running
or do you turn it off? They don’t know.”22
3.3.1.2 Processes of End-of-Life with an LVAD
Another common theme identified by investigators for all three studies was a
desire by patients and caregivers to understand how an LVAD would affect the process of
end-of-life. A number of caregivers discussed the need for a detailed plan that described
how the pump would be turned off when the end-of-life was near.23 Caregivers also
expressed confusion about whether death could even occur with the LVAD in place.21
This lack of understanding by the patients and the caregivers regarding what end-of-life
would be like was central throughout the qualitative interviews, and was compounded by
the lack of answers from providers. Investigators from all three studies concluded that
there is a desire from patients and caregivers for a detailed outline of the process of end35

of-life and deactivation of the device once the time comes close. Below is an example of
caregiver quote related to this theme:
“But it just seemed that the rug got pulled out from under us. And we kinda didn’t
understand what was going on, and to what extent it all meant.”21
Patients and caregivers also expressed frustration related to the integration of
hospice and palliative care resources during the end-of-life processes. Some patients and
families felt like they were abandoned by their LVAD team when they were transferred
to hospice team, and wanted their primary LVAD team to guide them through the end-oflife, rather than a team full of strangers.23 Caregivers in a different study also voiced a
similar concern; they felt that the hospice and palliative care teams did not know how to
take care of the LVAD, and therefore did not feel comfortable taking care of the patient.21
They also voiced that when they had to call emergency personnel because their loved one
with an LVAD had collapsed, the emergency personnel had to no idea how to take care
of the patient and the caregiver was too upset to try to explain what to do to help.21 These
interactions with other teams, outside the LVAD team, demonstrate a lack of education of
other personnel who may come into contact with LVAD patients and their families
during the emotional time of end-of-life, and the detrimental effects it can have.
3.3.1.3 Ethical Issues of Deactivation of the LVAD
A third common theme focused on the ethical issues associated with the
appropriateness of deactivation of the LVAD at the end-of-life. McIlvennan et al. found
that six of the eight caregivers viewed deactivation of the LVAD as suicide, and one
participant described the deactivation as “not their decision” and “the Lord’s decision”.21
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This question of ethical permissibility of deactivation can negatively affect patients’ and
caregivers’ decisions at end-of-life and make it much more difficult for them to make a
decision.
3.3.2 Provider Opinion Studies
Three descriptive, web-based, studies were conducted with clinicians as
participants. In these studies, investigators studied physicians, advanced practice nurses
and physician assistants, and their opinions related to end-of-life care of patients with an
LVAD and their experiences with LVAD deactivation.24-26 Clinicians who provided data
for these studies included American cardiology clinicians,24 American hospice/palliative
medicine clinicians,24,25 and European cardiologists.26 Investigators for these three studies
used the same 41-item web based survey; however, investigators for only one study
included qualitative free-responses related to questions chosen by the investigator.24 None
of the investigators discussed validity or reliability of the survey instrument, or details
related to development of the instrument. One investigator did describe domains in the
survey, which included, “LVAD as a life-sustaining therapy”, “Complexities of the
process of LVAD deactivation”, “Ethical and legal considerations of LVAD
deactivation”, “Honoring requests for turning off an LVAD in a patient who is not
nearing death”, and “Believe the underlying disease- heart failure- is the cause of death in
a patient who dies after their LVAD is turned off”.24
Overall, comparison among the various specialties and geographic locations
revealed few similarities. Geographically, a greater proportion of Europeans physicians
described death post-deactivation of the LVAD as “euthanasia or physician-assisted
suicide (European 27%, American 4%, p < 0.001)”.26 American physicians were more
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likely to report that they had deactivated an LVAD at the request of a patient compared
with European physicians (European 50%, American 82%, p < 0.004).26 Investigators
concluded that cultural, ethical, legal, historical, and socio-psychological variations can
be based on geographical differences, and these differences are evident in clinicians
opinions regarding end-of-life care with an LVAD.26
In the studies that examined hospice and palliative medicine providers and
cardiology providers, significant differences between the two groups, and individually
within the groups, can be seen.24,25 Hospice and palliative care medicine providers
demonstrated a very high rate of involvement with deactivation or end-of-life discussions
and experiences, with around 96% of clinicians involved with a deactivation of an
LVAD.25 This involvement in care was much smaller in cardiology providers, with only
42% being involved in the deactivation of an LVAD.26 Along with personal experiences
of deactivation, a difference of opinion about the ethical permissibility of deactivation
was also seen between the various clinician specialties. Hospice and palliative medicine
providers believed that deactivation was a patient and caregiver decision, with 72% and
88% in the various studies believing that a patient did not need to be “dying” to decide to
deactivate their LVAD,24,25 while only 57% of cardiology providers believed that it would
be acceptable to deactivate the LVAD if the patient is not actively dying.24
The qualitative portion of the web-based survey allowed participants to elaborate
on their survey answers in an open-ended way.24 When answering the question of
whether heart failure is the cause of death when an LVAD is deactivated, a cardiology
clinician, specifically a cardiothoracic surgeon, stated that, “Turning off an LVAD from a
completely conscious patient amounts to euthanasia”.24 However, a hospice and palliative
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care physician responded to the same questions by stating, “The act of turning off the
machine is not the cause of death; the disease is the cause of death”, these dichotomous
responses between the participants demonstrate the complex issues related to end-of-life
decision making among providers of patients with an LVAD.24
3.3.3 Quality Evaluation Results
In Tables 3.2, 3.3, and 3.4 quality evaluation of the various studies included in
this review using the MMAT tool are presented. Overall, the majority of the articles had a
low-quality rating, due to lack of information provided by authors related to
methodology. The qualitative studies had slightly better overall quality compared to the
quantitative studies, however, all three articles could have benefited from more
descriptive quotes from the interviews to corroborate the conclusions made by the
authors. The quantitative descriptive studies completed by Swetz et. al,25,26 needed much
more explanation of the survey used, including reliability and validity statistics. These
studies also lacked explanation for the low response rates, which could have led to biased
conclusions. The mixed-methods study also lacked a description of exactly how the
qualitative portion was integrated within the quantitative study, and how the results of the
various methods agreed or disagreed with one another.21
3.4 Discussion
Despite the high mortality rate of patients with an LVAD, there are still large gaps
in our understanding of the various aspects of end-of-life care for patients, caregivers,
and their clinicians. Investigators using qualitative methods determined that patients with
an LVAD and their caregivers reported high levels of confusion and frustration when the
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end-of-life approached, and often had unanswered questions about what the end-of-life
would be for them. This suggested that there was a lack of preparation and guidance of
patients and their caregivers regarding end-of-life from health care providers. However,
end-of-life care and decisions should be a point of emphasis for this population due to the
nature of the underlying pathology, the high-risk of the LVAD surgery, and the potential
for complications following implantation, including stroke and infection.7
Despite the lower quality of the qualitative research, the conclusions reached by
the investigators were all similar; providers of patients with an LVAD must do a better
job educating their patients about end-of-life. Several investigators are currently involved
in this kind of work; researchers are developing preparedness planning tools for LVAD
patients and their families to ensure that before and after implantation, they know what to
expect regarding deactivation and death, as well as incorporating teaching on advanced
directives.16-18,27 These types of interventions could meet the needs voiced by many
patients and caregivers in these studies, and create a more cohesive decision-making
process at the end-of-life.
Results from the provider opinion studies may explain the frustration and
confusion experienced by caregivers and patients with an LVAD. While addressing the
needs of patients and caregivers through preparedness planning, we are missing a crucial
stakeholder involved in the end-of-life decision making processes. Providers of patients
with an LVAD also need more guidance about how to handle end-of-life decision making
processes. To date, there have been no studies focused on provider education related to
end-of-life with an LVAD, and this review demonstrates this is a major gap in this area.
Clinicians in the palliative care field seem to be proactive in trying to educate their
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field,28 however, it does not seem that providers in other fields are changing their
practices to ensure they are meeting the needs of this unique group of patients and their
families. This provider gap could be attributed to the vague guidance provided by the
professional organizations of their fields. There needs to be more guidance from
professional organizations that advise providers about the ethical implications of
deactivation, as well as in-depth guidance on the role of providers in educating patients
and their families about end-of-life with an LVAD.
There is also a disconnect between patient and provider opinions on end-of-life
discussions. Participants in the qualitative study expressed that they felt unprepared, and
many say that had never had these types of end-of-life care discussions with their
providers. However, providers in the quantitative studies often said they had experiences
with these types of discussions with their patients and families. This could be due to a
lack of conversation had between providers and their patients and families. Providers feel
as though the subject has been broached by bringing up an area such as end-of-life, but
patients and families may not have fully grasped what the providers were saying or did
not feel that their needs were fully met. This could be an example of the lack of shareddecision making.
As discussed before, researchers in the field who have discussed end-of-life in
published editorials acknowledge the lack of shared decision-making in these
processes.12,13 This is seen in the confusion and frustration voiced by all shareholders in
the area of end-of-life decision making for patients with an LVAD. More research
emphasis needs to be placed on interventions that can increase and improve
communication between providers and LVAD patients and their families focusing on
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end-of-life discussions. This type of research could aim to identify gaps between what
providers feel they are discussing with their patients versus what patients feel has been
discussed, then interventions can focus on filling this gap. This type of shared decisionmaking could also alleviate some of the ethical concerns that have arisen by having more
open lines of communication between the various groups involved.
While the literature review demonstrates several gaps regarding end-of-life care
for patients with an LVAD, the ultimate gap is the lack of credible studies on the subject
itself. Multiple types of studies, including quantitative, qualitative, and mixed-methods
were included because there were not enough of any one type to create a comprehensive
review. Moving forward, research must focus on creating high-quality studies that
examine end-of-life with an LVAD for all the stake-holders, both through quantitative
and qualitative methods, and examine the various system level factors associated with
these decision-making processes.
3.5 Limitations
There were several limitations of this review. Only articles published in English
were included, so some studies with important conclusions may not have been evaluated.
Second, due to the relative limited availability of studies, multiple different types of
studies were included, which limited the ability of the reviewers to compare the studies to
one another directly, therefore we used the MMAT tool to compare them. A primary
limitation is the lack of investigations of end-of-life care, and the lack of high quality
studies related to end-of-life care in patients with an LVAD, which leads to decreased
ability to draw conclusions about the research.
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3.6 Conclusion
Based on the review of these six studies, providers, caregivers, and patients with
an LVAD are struggling with end-of-life issues and care. There is a lack of provider
education about end-of-life with an LVAD, and patients and their caregivers are
experiencing high levels of confusion and frustration about what to expect at the end-oflife. Further research is needed to create more comprehensive guidelines for end-of-life
care for patients with an LVAD. Future studies should focus on patients with an LVAD
experiences regarding end-of-life discussions with their provider and caregivers.
Research is needed on providers’ experiences, attitudes, and knowledge about end-of-life
discussions with their patients who have an LVAD, and quantitative analysis regarding
factors that impact patients’ comprehension of end-of-life discussions with their
providers.
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Table 3.1 Studies Included in Integrative Review
First Author

N/Sample

Methods/

(Year)

Findings

Measurements

Type of
Study
Location
Qualitative Studies
Barg (2017)

n= 39 patients

Qualitative-

n= 42 caregivers

Grounded
Theory

Open-ended,

Potential to save or “being

semi-structured

saved”- created a sense of

interviews with

moral obligation to

caregivers and

undergo procedure

patients
Multi-site

“Living in liminal state”patients describe
uncertainty of what death
with an LVAD would be
like, lots of unanswerable
questions to providers

Brush

n=20 caregivers of

3 open-ended

Most patients did not

(2010)

recently deceased

questions of

think about death very

caregivers
(completed within
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Qualitative

patients with an

2 weeks of death

often when QOL was

Descriptive

LVAD as DT

of patient with an

acceptable

LVAD as DT)

Single-site

Open discussion with the
LVAD team crucial
All expressed relief when
detailed plan for
withdrawal was outlined
Ongoing communication
with LVAD team “in
concert” with hospice
teams very important to
patient and family
members

McIlvennan

n= 8 bereaved

In-depth semi-

3 main themes: 1)

(2016)

caregivers of patients

structured

overwhelmed with

with an LVAD

interviews with

process of death with an

caregivers of

LVAD, 2) different

patients who died

beliefs about the legal and

with an LVAD

ethical principles related

Qualitative
Descriptive
Single-site

to deactivation of the
LVAD, and 3) lack of
integration of resources at
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the EOL, was a major
source of confusion and
abandonment for
caregivers.
Provider Opinion Studies
McIlvennan

n= 440 survey

41-item web-

Comparison of HPM and

(2017)

respondents, n=269

based survey

cardiology clinicians’

cardiology clinicians

along with free

views on aspects of

response section

LVAD deactivation and

on some items to

EOL. Quantitative and

allow for

qualitative evaluation

qualitative

demonstrated lack of

analysis about

consensus between

deactivation of the

providers. Authors

LVAD and other

concluded that this

LVAD EOL

extreme difference in

concerns

opinion could lead to

Mixedmethods
Multi-site

n= 122
hospice/palliative
medicine clinicians

confusions for patients,
loved ones and other
health care providers.

46

Swetz

n=303 clinicians

41 item web-based

There were several

(2013)

who care for patients

survey regarding

significant differences

with an LVAD.

deactivation of the

between European and

Comparison of

LVAD and other

North American

European versus

LVAD EOL

clinicians. Europeans

North American

concerns

physicians were less likely

Crosssectional
correlational
study
Multi-site

clinician opinions on

to endorse the

LVAD deactivation

permissibility of

and EOL

deactivating the LVAD,
as well as considering
deactivation of the LVAD
as physician-assisted
suicide/euthanasia
(p<.05). The researchers
concluded that more
consensus and guidance is
needed to help clinicians
regarding education of
patients with an LVAD
and their caregivers.
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Swetz

n= 122 hospice/

41 item web-based

Descriptive statistics

(2015)

palliative care

survey regarding

described the results

medicine clinicians

deactivation of the

related to HPM clinicians’

LVAD and other

experiences and opinions

LVAD EOL

regarding varying aspects

concerns

of LVAD deactivation.

Crosssectional
correlational
study

The researchers concluded
Multi-site

that compared to other
physician groups HPM
clinicians support the
ethicality of LVAD
deactivation and support
patient autonomy.

Legend: DT- destination therapy, EOL-end-of-life, HPM- hospice/palliative care
medicine, LVAD- left ventricular assist device

Table 3.2 Quality Evaluation of Qualitative Studies
First

Qualitative

Qualitative

Findings

Interpretatio

Coherence

Author

approach

data collection

adequately

n of results

between

(Year)

appropriat

methods

derived

sufficiently

qualitative
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Type of

e to

adequate to

from the

substantiated

data sources,

Study

answer

address

data

by data

collection,

research

research

analysis, and

question

question

interpretation

Yes

Yes, coding

Yes,

Yes, authors

Yes,

and data

however,

corroborated

however,

management

some

extensively

some quotes

discussed

quotes did

with other

seemed to be

not seem

research

linked to a

to be

done in the

different

completely

field and

theme that

coherent

discussed

the authors

with the

how this was

did not

theme

an extension

include,

of prior work

however,

Location

Barg
(2017)
Qualitative
- Grounded
Theory
Multi-site

interpretation
/ conclusion
seemed
coherent and
appropriate
Brush
(2010)

Yes

Cannot tell,

Cannot

No, very

Cannot tell,

coding

tell,

little actual

authors used
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Qualitative

methods were

patient

data from the very few data

Descriptive

not discussed

quotes

interviews is

sources when

were not

seen, so

drawing

used in the

interpretatio

conclusions,

results

n is

and their data

section

somewhat

was not

difficult to

shown in

agree with

depth

Single-site

McIlvenna
n (2016)
Qualitative
Descriptive
Single-site

Yes

Yes, authors

Yes,

Yes,

Yes, authors

discussed

quotes

extensive

used outside

framework for

used

quotes from

sources to

data

extensivel

interviews

connect with

collection,

y to

were used

their

coding

elaborate

and

conclusions

extensively

on

corroborate

from the

discussed, and

thematic

findings

data, and

qualitative

discoverie

from the

interpretation

data

s

authors

was cohesive

trustworthines
s was detailed
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Table 3.3 Quality Evaluation of Quantitative Descriptive Studies
First

Samplin

Sample

Measurements

Risk of

Statistical

Author

g

representativ

appropriate

nonresponse

analysis

(Year)

strategy

e of target

bias low

appropriat

relevant

population

Type of
Study
Location

e to

to

answer

address

the

research

research

question

questions

s
Swetz
(2013)
Crosssectional
Quantitativ
e
Descriptiv
e

Yes

No—only

Cannot tell-

Cannot tell-

4% response

very little

authors did not

rate

reliability/validit

discuss

y information

whether they

explained

sent the survey

regarding the

multiple times,

survey; does

how long

discuss that it

participants

was pilot-tested

had to

with heart

complete the

failure and

survey, or if
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Yes

palliative

they sent

medicine

reminders

physicians
Swetz

Yes

(2015)
Crosssectional

Cannot tell-

Cannot tell-

Cannot tell-

reported

very little

due to

response

information on

‘crowdsourcin

rate of ‘less

the survey used

g’ and using a

than 10%’

Quantitativ

Yes

roster from a
national

e

organization

Descriptiv

authors

e

acknowledge
difficulty in
this area

Table 3.4 Quality Evaluation of the Mixed Methods Study
First

Adequate

Different

Outputs of

Divergences

Do the

Author

Rational

components

the

and

different

(Year)

for

of the study

integration

inconsistencies

components

mixed-

effectively

of

between

of the study

methods

integrated to

qualitative

quantitative and

adhere to

design to

answer

and

qualitative

the quality

Type of
Study
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Location

address

research

quantitative

results

criteria of

research

question

components

adequately

each

adequately

addressed

tradition of

questions

interpreted

the methods
involved

McIlvennan
(2017)
Mixedmethods
Multi-site

Yes

Cannot

Yes-

Cannot tell- the

Cannot tell-

tell—it is

authors

divergences

very little is

unclear

grouped

between the

described

whether

results into

comparison

regarding

each of the

domains

groups is

the

41 questions

and

adequately

qualitative

in the

integrated

discussed,

portion of

survey had a

both

however, it is

data

qualitative

qualitative

not discussed

collection,

component

and

whether there

and the

or just a

quantitative

were any

quantitative

selected few

results into

between the

portion is of

from the

the various

qualitative and

relatively

researchers

domains

quantitative

low quality

data
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Figure 3.1 Flow Chart of Articles Included in Integrative Review

68 records identified through database searches
using PubMed, CINAHL, and PsycINFO

59 records after duplicates removed
46 articles excluded after
abstract review
13 full-text articles reviewed for eligibility

7 articles excluded after full review:
- 4 articles related to preparedness
planning at end-of-life
- 3 articles aims not related to
inclusion/exclusion criteria

6 articles are included in this review

CHAPTER FOUR. PSYCHOMETRIC TESTING OF THE CONTROL-ATTITUDES
SCALE-REVISE FOR PATIENTS WITH A LEFT VENTRICULAR ASSIST DEVICE
4.1 Introduction
Perceived control is a broadly studied construct that primarily focuses on an
individual’s perception that they can positively influence outcomes related to stressful
situations.1 In healthcare, perceived control is often linked with the ability to positively
cope with a diagnosis and management of chronic disease, particularly heart failure
(HF).2-4 As of 2018, HF affected approximately 6.5 million Americans.5 To treat endstage HF, many patients receive a left ventricular assist device (LVAD); since the
development of these devices, over 17,000 people have received an LVAD and the
indications for implantation are increasing.6
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Patients with an LVAD face much of the same disease burden as those with
medically managed HF, however, patients with an LVAD have extremely unique needs
related to life with a device. Health related quality of life (HRQOL) is an evolving
concept in the LVAD literature; researchers have shown that HRQOL is associated with
anxiety and depression in patients with an LVAD, similar to other cardiac populations. 7
It has been shown in the HF population that poor perceived control is related to decreased
HRQOL, as well as strongly correlated with anxiety and depressive symptoms.2,8 In
patients with an internal cardioverter defibrillator (ICD) a qualitative analysis revealed
that perceived control was the core theme related to psychological adjustment to living
with a device.9 Perceived control is often one of the main targets of nursing interventions,
as it is considered modifiable factor. Despite understanding the critical role that perceived
control plays in similar patient populations, perceived control has never been examined in
the LVAD population.
To more thoroughly understand the role perceived control plays, it is critical to
have a validated measure to assess it. Currently, the Control Attitudes Scale-Revised
(CAS-R) is the primary perceived control assessment scale used in cardiac populations.8
The purpose of this study was to evaluate the reliability and validity of the CAS-R in the
LVAD population. The specific aims were to: 1) assess internal consistency and
homogeneity of the CAS-R; and 2) provide evidence of construct validity with factor
analysis and hypothesis testing using the following hypotheses:
•

Hypothesis 1a: Patients with higher levels of perceived control will have
less depressive symptoms
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•

Hypothesis 1b: Higher levels of perceived control will be independently
associated with lower levels of depressive symptoms in a multivariate
regression analysis

•

Hypothesis 2a: Patients with higher levels of perceived control will have
lower levels of anxiety

•

Hypothesis 2b: Higher levels of perceived control will be independently
associated with lower levels of anxiety symptoms in a multivariate
regression analysis

4.2 Background
The initial Control Attitudes Scale was created in 1995 by Moser and Dracup due
to lack of a validated measure of perceived control in cardiac patients, and the relevance
that perceived control had shown to possess in clinical practice.10 The initial four-item
scale demonstrated good validity and reliability in several studies of cardiac patients,10,11
however, the authors found that when a participant did not have a significant support
person in their life, the scale had poor reliability.8 To address this phenomenon, the
authors revised the initial four-item scale and added components from the Rheumatology
Attitudes Scale;12 this revision and addition resulted in a 19-item Cardiac Attitudes
Index.8 After extensive psychometric evaluations of the 19-item scale, the authors
deleted 11 items, leaving the 8-item CAS-R most commonly used in research today.8
The 8-item CAS-R was validated in a large cohort over 4,000 participants with
various cardiac diseases and shown to have excellent reliability and validity.8 The
Cronbach’s alpha of the sample was greater than 0.7, indicating good reliability.8
Construct validity of the CAS-R, using convergent validity, was tested by examining the
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relationship of perceived control to anxiety and depression. In prior studies, those with
lower anxiety and depression symptoms had higher levels perceived control.10,11,13
Validity was confirmed using hypothesis testing of these prior findings, showing in the
sample of 4,000 cardiac participants that higher perceived control was associated of
lower levels of anxiety and depressive symptoms.8
To our knowledge, perceived control has not been measured and reported in the
LVAD population. As the LVAD population continues to increase in number, it is crucial
to understand the role that perceived control plays in the QOL of these patients. In a
systematic review of the literature related to quality of life with an LVAD, authors found
that QOL is not well understood due to limitations of our current instruments to measure
this concept.14 One finding that was consistent in this review was that adaptation to
device management was a difficult process and that this process takes significant
emotional and physical adaptation.14 Additionally in the LVAD population, levels of
depression and anxiety are higher than in the general population, similar to that of other
chronic disease states.15 However, we do not know the role perceived control may play or
if it is valid measure of this concept in this population.
4.3 Methods
In this secondary analysis of perceived control, depressive symptoms and anxiety
symptoms in 89 patients with an LVAD. This sample was drawn from a larger
prospective research study described in more detail elsewhere.16 Sociodemographic data
were collected through self-report and inspection of the medical record. Institutional
review board approval was obtained, and all participants gave written informed consent.
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4.3.1 Measures
4.3.1.1 Control Attitudes Scale-Revised
The 8-item instrument (Table 4.2) was completed by each participant
individually. The total score ranges from 8-40, with lower scores indicating lower levels
of perceived control.8 Each scale item is rated on a 5-point Likert scale, with 1 being
totally disagree, and 5 being totally agree. Item numbers 5 and 8 are reverse coded. The
instrument is typically completed in less than 2 minutes and is between a fourth and fifth
grade reading level.8
4.3.1.2 Patient Health Questionnaire-9
Depressive symptoms were measured using the Patient Health Questionnaire-9
(PHQ-9), which consists of nine items. Each item corresponds to one of the nine
symptoms of the major depressive disorder criteria of the Diagnostic and Statistical
Manual of Mental Disorders-IV. Patients rated items based on how often they
experienced these symptoms over two weeks on a 4-point Likert scale ranging from 0
(not at all) to 3 (nearly every day). The scores are totaled with a range of 0 to 27. Higher
scores on the PHQ-9 indicate higher levels of depressive symptoms. The reliability and
validity of the PHQ-9 has been demonstrated extensively in a number of populations as a
screening instrument for depression and a measure of depressive symptoms among those
at risk for or with cardiac disease.17-19 The PHQ-9 had demonstrated high specificity and
predictive value in relationship with other clinical measures of depression.17-19 In this
sample of LVAD patients the Cronbach’s alpha was 0.845, indicating good internal
consistency.
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4.3.1.3 Brief Symptom Inventory Anxiety Subscale
Anxiety symptoms were measured using the Brief Symptom Inventory (BSI)
anxiety subscale. This is a 6-item subscale is used to measure the intensity of anxiety
symptoms over the past 7 days.20 The items are scored on a 5-point Likert scale from 0
(not at all distressed) to 4 (extremely distressed). The total sum of scores range from 0 to
24, with higher scores indicating higher levels of anxiety symptoms. In this sample of
LVAD patients the Cronbach’s alpha was 0.840, indicating good internal consistency.
4.3.2 Data Analysis
All statistical analyses were conducted using SPSS version 24. Frequencies and
percentages or mean and standard deviations were used to describe the sample. The
sample was divided into high and low perceived control groups by the median score of
the sample, due to the skewness of the data and recommendation of the initial author of
the scale. Independent t-tests and chi-square tests were used to test for differences
between the high versus low perceived control groups. A probability value of less than
0.05 was considered to be statistically significant.
4.3.2.1 Reliability
Internal consistency reliability was assessed using Cronbach’s alpha. A
coefficient of greater than 0.7 is considered acceptable internal consistency reliability, a
score of 0.8 is considered good internal consistency.21 Further reliability analyses were
conducted using inter-item and item-total correlations to assess for homogeneity of the
scale. Inter-item correlation coefficients greater than 0.2 and less than 0.7 demonstrate
that the individual items uniquely contribute to the scale and are not redundant.21 Item59

total correlations greater than 0.2 indicated that the scale items make an individual
contribution to the scale.21
4.3.2.2 Validity
Factor analysis was completed to test construct validity. We used exploratory
factor analysis to examine the number of factors this scale measured in the LVAD
population. Principal component analysis was utilized, and if more than one factor
loaded, varimax rotation was used to provide a more complete understanding of the
variance each item explained per factor. In order to ensure that factor analysis was
appropriate, we evaluated the Kaiser-Meyer-Olkin statistic; higher values indicated that
the sample would be appropriate for factor analysis.21 Bartlett’s test of sphericity was also
examined to ensure that the correlation matrix of the items was not an identity matrix,
which would indicate that factor analysis would not be appropriate.21 In Bartlett’s test, a
p-value of less than 0.05 is indicative that the sample is appropriate for factor analysis.21
In principal component analysis, Eigenvalues of one and above were retained. In the
scree plot analysis, we will look for a point where the shape of the curve changes, this
indicates that the factors above the curve change account for the most significant amount
of variance.
Convergent validity was verified using hypothesis testing. Two hypotheses were
tested in which we examined the relationship of perceived control with depressive and
anxiety symptoms. Prior research has shown that high levels of perceived control were
related to lower levels of depressive symptoms and lower levels of anxiety
symptoms;8,10,11 therefore, an instrument that is psychometrically established in the
population should also demonstrate the same relationships.8 In this sample, hypothesized
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relationships between high levels of perceived control and lower levels of depressive and
anxiety symptoms were tested.
To test Hypothesis 1a, that higher levels of perceived control are associated with
lower levels of depressive symptoms in LVAD patients, a two group, t-test analysis was
utilized. High and low groupings of perceived control were used as the independent
grouping variable, and total score on the PHQ-9 was used as the dependent variable. To
test Hypothesis 1b, a multivariate linear regression analysis was used, with total score on
the PHQ-9 as the dependent variable, and total score on the CAS-R, after controlling for
age, gender, education level, and whether the participant lived alone.
To test Hypothesis 2a, that higher levels of perceived control are associated with
lower levels of anxiety symptoms in LVAD patients, a two group, t-test analysis was
used. High and low groupings of perceived control were used as the independent
grouping variable, and total score on the BSI anxiety subscale was used as the dependent
variable. To test Hypothesis 2b, a multivariate linear regression analysis was used, with
total score on the BSI anxiety subscale as the dependent variable, and total score on the
CAS-R, after controlling for age, gender, education level, and whether the participant
lived alone.
4.4 Results
Baseline demographic information was collected prior to LVAD implantation,
and other measures were collected 1-month post LVAD implant. Summary statistics for
the sample are presented in Table 1. The CAS-R scores were slightly negatively skewed,
as assessed by normality plots and histograms. The median score of the CAS-R (30) was
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used to divide the sample into two groups, high perceived control (46% of the sample)
and low perceived control (54% of the sample). The sample was 80% male, which is
consistent with the LVAD population in the United States currently.6 When comparing
the high versus low perceived control groups, there were three significant differences
between the groups (Table 4.1). Those with higher perceived control had significantly
higher scores of the CAS-R, with a mean score of 34 ± 2.6, compared to those with lower
perceived control whose mean scores were 25 ± 4.8. Those with higher perceived control
also had on average lower scores on the PHQ-9 compared with those with lower
perceived control. Lastly, those with higher perceived control had lower scores on the
BSI Anxiety subscale compared to the lower perceived control group.
4.4.1 Reliability
Cronbach’s alpha of the CAS-R was 0.867, indicating good internal consistency.
Overall, the inter-item correlation coefficients were less than 0.8 indicating little to no
redundancy among the items. All correlation coefficients were greater than 0.2, indicating
that the items were related to one another (Table 4.3). Item-total correlations were all
greater than 0.3, indicating that each item made a unique contribution to the scale (Table
4.4). There were also no items from that scale that if removed would make the
Cronbach’s alpha increase (Table 4.4), another indicator of good reliability of the scale.
4.4.2 Validity
Construct validity was tested using exploratory factor analysis. To test that factor
analysis was appropriate the Kaiser-Meyer-Olkin statistic was run, with a result of 0.828.
The Bartlett’s test p-value was less than 0.001, indicating that factor analysis was
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appropriate to conduct in this sample. Through exploratory factor analysis, one factor
loaded with an Eigenvalue of 4.183. This indicates that the CAS-R in the LVAD
population is only measuring one construct. The factor explained 52% of the variance in
the responses. Table 4.5 demonstrates the loadings of each individual items under the one
factor.
In testing Hypothesis 1a, a two-group t-test demonstrated that the relationship of
perceived control on depressive symptoms was significant (Table 4.6). When testing
Hypothesis 1b, perceived control was independently associated with depressive
symptoms in a multivariate linear regression analysis, including age, gender, education,
and whether they lived with someone, as well as perceived control was the only
significant predictor of depressive symptoms (Table 4.7).
In Hypothesis 2a, a two-group t-test demonstrated that the relationship of
perceived control on anxiety symptoms was significant (Table 4.8). A multivariate linear
regression analysis to test Hypothesis 2b included age, gender, education, whether they
lived with someone, and perceived control and showed that perceived control was the
only variable independently associated with anxiety symptoms in the model (Table 4.9).
4.5 Discussion
The results of this study provide evidence that the 8-tem CAS-R is a reliable and
valid measure of perceived control in the LVAD population. Reliability testing evidence
from Cronbach’s alpha coefficient, inter-item correlations, and item-total correlations,
indicate that the CAS-R had good internal consistency. Evidence of validity was also
provided through construct validity testing and convergent validity hypothesis testing.
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The CAS-R loaded on only one factor, indicating that the scale was only measuring one
construct, that of perceived control. This is similar to other factor analyses done of the
CAS-R.8 We were also able to observe that patients with LVAD who had higher levels of
perceived control, had lower levels of anxiety and depressive symptoms, similar to other
cardiac populations.8,13
It is critical to have a validated instrument of perceived control in this population
because of our lack of understanding of predictors of good quality of life with an
LVAD.14,15 In other populations, especially populations with a cardiac device, there is
evidence of the important role that perceived control plays in positive outcomes,4,9,10,13
however, this had not been demonstrated in the LVAD population. A reliable and valid
scale will help clinicians and researchers to accurately identify the role perceived control
plays in patients with an LVAD. Improving perceived control would ideally be a target
for interventions that can improve quality of life and broaden our understanding of what
life with a device truly entails.
4.6 Conclusion
This study demonstrates that the CAS-R is a reliable and valid instrument to use
in the LVAD population to measure perceived control. Clinicians and researchers can use
the instrument to identify the role perceived control plays in outcomes of patients with an
LVAD and target ways to improve perceived control among these patients.
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Table 4.1 Participant Characteristics, N= 89
All Participants,
Mean±SD

Higher

Lower

Perceived

Perceived

Control

Control

n= 41 (46)

n=48 (54)

p-value

or n (%)

Age (years)

53 ± 14

53 ± 16

53 ± 12

0.844

Gender (male)

81 (80.2)

55 (57)

41 (43)

0.538

CAS-R

29.1 ± 6

34 ± 2.6

25 ± 4.8

<0.001

PHQ-9

6.4 ± 5.3

4.3 ± 3.7

8.1 ± 6

<0.001

BSI Anxiety Subscale

3 ± 3.6

1.9 ± 2.9

3.9 ± 3.9

0.005

Legend CAS-R: Control Attitudes Scale-Revised; PHQ-9: Patient Health Questionnaire-9;
BSI: Brief Symptom Inventory
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Table 4.2. The Control Attitudes Scale-Revised
Items
1. If I do all the right things, I can successfully manage my heart condition
2. I can do a lot of things myself to cope with my heart conditions
3. When I mange my personal life well, my heart condition does not bother
me as much
4. I have considerable ability to control my symptoms
5. No matter what I do, or how hard I try, I just can’t seem to get relief from
my symptoms*
6. I am coping effectively with my heart condition
7. Regarding my heart problems, I feel lots of control
8. Regarding my heart problems, I feel helpless*
Legend: * reverse coded
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Table 4.3 Inter-Item Correlation of the CAS-R, overall Cronbach’s Alpha 0.867
Item 1

Item 2

Item 3

Item 4

Item 5

Item 6

Item 7

Item 1

1.00

Item 2

0.516

1.00

Item 3

0.546

0.563

1.00

Item 4

0.459

0.523

0.544

1.00

Item 5

0.536

0.318

0.416

0.264

1.00

Item 6

0.440

0.524

0.297

0.346

0.272

1.00

Item 7

0.506

0.445

0.603

0.696

0.414

0.437

1.00

Item 8

0.471

0.338

0.368

0.326

0.539

0.446

0.484

Legend: CAS-R: Control Attitudes Scale-Revised
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Item 8

1.00

Table 4.4. Item-Total Statistics for the CAS-R
Item-Total Correlation

Cronbach’s Alpha if item
deleted

Item 1

0.687

0.844

Item 2

0.629

0.850

Item 3

0.667

0.846

Item 4

0.626

0.851

Item 5

0.532

0.860

Item 6

0.531

0.860

Item 7

0.725

0.838

Item 8

0.574

0.856

Legend: CAS-R: Control Attitudes Scale-Revised
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Table 4.5 Factor Loadings for the CAS-R
Loadings for Factor 1
Item 1

0.779

Item 2

0.735

Item 3

0.762

Item 4

0.731

Item 5

0.639

Item 6

0.639

Item 7

0.804

Item 8

0.676

Table 4.6 Differences in depressive symptoms based on high versus low levels of perceived
control (N=89)

PHQ-9 Total Score

Low Perceived

High Perceived

Control (n=48)

Control (n=41)

8±6

4.4 ± 3.7

P-value

0.001

Legend: F statistic 11.915, Brown-Forsyth p-value 0.001 (Levene p-value 0.002); PHQ-9patient health questionnaire-9
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Table 4.7 Multivariate Linear Regression Model: Perceived control as an independent predictor
of depressive symptoms (N=89)
Beta

95% Confidence

b

SE

P-value

Interval
CAS-R total

-0.392

-0.563- -0.222

-0.446

0.086

<0.001

Age

0.013

-0.063-0.088

0.033

0.038

0.740

Gender (male)

1.295

-1.163-3.753

0.102

1.236

0.298

Education

0.378

-0.395- 2.915

0.96

0.389

0.334

-0.372

-3.658- 2.915

-0.022

1.652

0.823

score

Level
Living Alone
(check about
this) 0=alone,
1= with
someone
Legend: overall p-value 0.001; B: standardized beta coefficient; SE: standard error; overall
adjusted r-square 0.177
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Table 4.8 Differences in anxiety symptoms based on high versus low levels of perceived
control (N=89)

BSI Anxiety Subscale

Low Perceived

High Perceived

Control (n=48)

Control (n=41)

3.9 ± 3.9

1.9 ± 2.9

P-value

0.005

Total Score
Legend: F statistic 8.127, Brown-Forsyth p-value 0.005 (Levene p-value 0.035); BSI- Brief
Symptom Inventory Anxiety Subscale
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Table 4.9 Multivariate Linear Regression Model: Perceived control as an independent predictor
of anxiety symptoms (N=89)
Beta

95% Confidence

b

SE

P-value

Interval
CAS-R total

-0.186

-0.308--0.065

-0.317

0.061

0.003

Age

0.002

-0.052-0.056

0.007

0.027

0.947

Gender (male)

1.338

-0.410- 3.086

0.157

1.236

0.132

Education

0.053

-0.497-0.603

0.020

0.389

0.849

-0.317

-2.653- 2.020

-0.028

1.652

0.788

score

Level
Living Alone
(check about
this) 0=alone,
1= with
someone
Legend: overall p-value 0.047; B: standardized beta coefficient; SE: standard error; overall
adjusted r-square 0.071

CHAPTER FIVE. END-OF-LIFE ATTITUDES AND EXPERIENCES OF PATIENTS
WITH A LEFT VENTRICULAR ASSIST DEVICE
5.1 Introduction
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Patients with advanced heart failure (HF) were historically treated with medical
management only; however, in the last 10 years the use of advanced surgical treatment
options, such as a left ventricular assist device (LVAD), have become viable treatment
options. Since the Food and Drug Administration (FDA) first approved LVADs for use as
bridge to heart transplantation in 1994, the science and rapid utilization of these devices
has grown exponentially.1 Between 2008 and 2017, over 17,000 LVAD’s were implanted
in the United States,2 and that number will continue to grow due to the lack of available
donor hearts and the growing number of Americans with HF.3,4
While scientific advancements such as LVADs increase life expectancy in some
individuals compared to optimal medical management,5 most recent data show that the
there is still a high mortality rate at one year of about 19%,2 and at times, poorer quality
of life than without an LVAD.6 The most common causes of death in the LVAD
population are neurologic complications, multi-system organ failure, and infection.7
There is also a possibility of pump thrombosis, which occurs when a large clot obstructs
flow through the device, causing the device to malfunction. When this occurs, a pump
exchange usually is required; however, patients who have a pump exchange exhibit much
higher rates of mortality compared to patients who have only one pump in their lifetime.7
Pump exchanges related to thrombus occur in about 7% of patients in the first year, and
up to 18% at year two.8 Thus, despite the life-prolonging capacity of LVADs, there are
still significant risks associated with the device that can ultimately lead to death.
Because of the high mortality rates, and increased morbidity and mortality
associated with pump exchanges,8 it is critical that patients who have been implanted
with an LVAD and their healthcare providers discuss end-of-life (EOL) situations and
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care. However, many LVAD providers have limited experience with deactivation, with
only 42% of American cardiologists having been involved in the care of a patient who
had their device deactivated.9 There are differing opinions among providers on how to
approach EOL discussions with patients who have an LVAD, and whether deactivation is
an ethical option.9-11 As a result of lack of provider consistency and knowledge on
broaching EOL discussions with this population, patients and caregivers often express
confusion and uncertainty about options for EOL with an LVAD, and report frustration
when attempting to get information from providers.11,12
The high incidence of cognitive impairment in patients with HF compounds
difficulties in shared decision making among patients, caregivers and providers.13
Cognitive impairment leads to blunted responses of HF patients, difficulty responding in
conversations, or slower responses to physiologic symptoms that indicate the need for
intervention.14 Mild cognitive impairment in the HF population is associated with higher
rates of readmissions and death,15 thus necessitating more urgent and thorough EOL
conversations.
To provide support and education for patients with an LVAD, an exploration of
experiences and attitudes about EOL issues is needed. Specifically, there is a need to
focus on patients’ feelings about living with their LVAD within the context of another
terminal illness or worsening of current illnesses, while also considering the impact of
cognitive function. This will help clinicians understand how experiences and attitudes
about the LVAD influence patient preferences when nearing EOL. The purpose of this
study was to explore patients’ attitudes and experiences about EOL related to LVAD
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deactivation and pump exchange and examine the impact of cognitive status on these
attitudes and experiences. The specific aims of this study were to:
Specific Aim 1: Describe patients’ attitudes and experiences of discussions with their
healthcare about pump exchange and LVAD deactivation at EOL.
Specific Aim 2: Determine the association of cognitive function with patients’ attitudes
and experiences toward pump exchange and LVAD deactivation.
5.2 Methods
5.2.1 Sample, Study Design, and Data Collection
This study was a cross-sectional correlational design. Patients with an LVAD
invited to participate met the following inclusion criteria: 1) had an implanted LVAD for
the treatment of end-stage heart failure; 2) LVAD was implanted for at least 30 days prior
to enrollment in the study; 3) able to complete a three-question cognition assessment and;
4) able to speak and write English. Exclusion criteria were: 1) less than 18 years of age
and 2) institutionalized or resided in an extended care nursing facility. Participants were
screened by a recruiter for eligibility. Those who met inclusion criteria and agreed to
participant were referred to the project directors who met with the participants to obtain
informed consent. Participants were asked to complete a questionnaire packet and
received $20 compensation for their time. Data collection took place between November
2018 and February 2019. This study was approved by the Institutional Review Board at
the University of Kentucky.
5.2.2 Demographic and Clinical Data
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Demographic data and health history were self-reported. Lab values, information
about LVAD therapy, such as pump exchange history, and implantable cardioverter
defibrillator (ICD) implantation were obtained through review of patients’ medical
record. Information regarding implant indication (destination therapy versus bridge to
transplant), date of implantation, pre-operative New York Hospital Association (NYHA)
class, and Intermacs profile (a clinical profile of health status at time of LVAD
implantation) were collected using the Intermacs database.
5.2.3 End-of-life with an LVAD Questionnaire
Patients’ experiences and attitudes about EOL were collected using a survey
initially created for patients with an implantable cardioverter defibrillator that was
modified to reflect the LVAD patient perspective.16 The End-of-Life with an ICD
Questionnaire (EOLICDQ) was modified with the assistance of the developer and the
modified instrument was called the End-of-Life with an LVAD Questionnaire (EOLLVADQ). The EOL-LVADQ is a 22-question survey that focuses on patients’ attitudes
and experiences about decision making surrounding EOL, specifically deactivation of the
LVAD and pump exchanges. Participants responded to the statements with either
agree/disagree, yes/no, or cannot take a stand. The items on this survey are not scored,
and therefore are not totaled; the items should be evaluated individually and responses
can be compared. The last six questions on the survey allowed participants to respond
with agree/disagree or ‘can’t take a stand’. Because, very few participants chose the
‘can’t take a stand’ response, those who chose this response were not included in the
analysis.
5.2.4 Cognition Assessment
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Cognition was evaluated in this study using the Montreal Cognitive Assessment
(MoCA), which is a brief cognitive screening tool, widely used in multiple populations to
identify mild cognitive impairment (MCI).17 Mild cognitive impairment is commonly
understood as a decline in one or more cognitive functions, which is not attributed to
other neuro-cognitive diseases such as dementia or Alzheimer’s.17,18 The MoCA has been
validated in the heart failure population as a reliable measurement of cognition and
MCI.19 The range of scores on the MoCA is 0-30. The cut-point recommended by the
authors was used in this study. Thus, a score of 0-25 was considered to meet the criteria
for MCI and scores 26 and above were categorized as normal cognition.18,20
5.2.5 Data Analysis
SPSS version 24 was used for data analysis. Frequencies and proportions, means
± standard deviations, and median, 25th, and 75th percentiles were used to describe
demographic and clinical characteristics. Comparison of demographic and clinical
characteristics, as well as experiences and attitudes about EOL decision making between
normal cognition and MCI groups was completed using X2 and independent t-tests.
Logistic regression analysis was used to determine whether MoCA score was an
independent predictor of whether participants had discussed end-of-life scenarios or
pump exchange with their providers. A p-value of less than 0.05 was considered
statistically significant.
5.3 Results
5.3.1 Sample Characteristics
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A total of 30 participants completed the questionnaire (Table 5.1), but one was
unable to complete the MoCA and was excluded from subsequent analyses. The majority
of the sample was male (76.7%), white (90%), and married (50%). Most were NYHA
class IV (70%) prior to implant, and had an Intermacs profile score of 2 or 3 (76.7%),
indicating progressive or acute decline of health status requiring inotropic support. Most
participants at the time of their interview had an LVAD implanted for destination therapy
(63.3%), indicating they were not currently a candidate for heart transplantation. The
mean number of days with LVAD therapy was 702, with a range of 34 days to 2,472
days. Most participants had an implantable cardioverter defibrillator (83.3%), and had not
had a pump exchange (90%). There was a high incidence of comorbidity burden in the
population. A total of 46.7% of the total sample had diabetes, 53.3% reported
hypertension, 20% had kidney failure, 60% reported either a history or current atrial
fibrillation, and 33.3% reported some type of lung disease, either chronic obstructive
pulmonary disorder or asthma. Four (13.3%) participants also reported a history of a
stroke in the past, and 12 (40%) reported they had a myocardial infarction prior to LVAD
implantation.
5.3.2 Cognitive Assessment
In the final sample of 29 participants, the average MoCA score was 23 ± 4, with
23 of the 29 participants (79%), scoring less than a 26 indicating MCI. The average score
of those participants with MCI was 22 ± 3, and the average score of those with normal
cognition was 28 ± 1 (p<0.001). Demographically, both groups were very similar,
however, one significant difference was that the group with normal cognition were more
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likely to be bridge to transplant patients (83.3%), compared to those with MCI (26.1%, pvalue 0.010; Table 5.1).
5.3.3 End-of-Life with an LVAD Questionnaire
To describe patients’ experiences and attitudes related to EOL decision-making,
responses from the EOL-LVADQ were evaluated. Overall, 69% of the participants
responded that they had discussed a pump exchange with their provider, and 58.6% said
they had discussed what turning off the LVAD involves with their provider. Only 3.4%
of the participants had ever considered asking their provider to turn off the LVAD at
some point. Over 80% of participants said they would want to have a pump exchange
even if their quality of life had not improved with their first pump, and 73% said they
would want to have a pump exchange even if they were seriously ill and suffering from
another disease besides HF. Only 48.3% of participants said they had discussed their
wishes regarding EOL and their LVAD with the next-of-kin, despite 75.9% stating they
had discussed their illness trajectory with their next-of-kin. When discussing when
providers should bring up questions regarding deactivation, 44.8% of the participants said
they would prefer to never have a deactivation discussion. A total of 86.2% thought that
toward the EOL, during the final days, deactivation should be discussed, but only 51.7%
said they felt it should be discussed if they were suffering from a different disease with a
poor prognosis, such as cancer.
To determine if cognition was associated with EOL decision making, we
compared the responses of participants who had a MoCA score of 0-25 (MCI) and those
with MoCA scores 26 and greater (Table 5.2). In general, there was very little variation in
the experiences and attitudes of the two cohorts. The only significant difference between
79

the two cohorts was that those who had MCI were more likely to report that they would
like to decide themselves if their LVAD was deactivated towards the EOL (p = 0.017).
Otherwise, the cohorts responded similarly.
5.3.3.1 Logistic Regression Analysis
Although a sample of 30 LVAD patients is considered relatively large in the
LVAD arena (only about 2500 LVADs are implanted each year), statistically it is small
and, we were unable to generate a stable regression model to evaluate the relationship
between cognition and EOL decision-making, controlling for other relevant covariates. In
bivariate analysis, total MoCA score was not a predictor of having a conversation with
provider or next-of-kin regarding discussions related to deactivating the LVAD or pump
exchange.
5.4 Discussion
The analysis we conducted provides initial insight for researchers and clinicians
to have a more thorough understanding of what patients with an LVAD have experienced
and feel about EOL decision making. Due to the high rates of mortality and lifethreatening complications associated with LVAD implantation, EOL conversations and
decision making are imperative. In order to be prepared for adverse events that may
occur, guidelines provided by professional organizations urge LVAD teams to discuss
EOL care, and integrate palliative care with patients and their families, even prior to any
EOL scenario.21,22 Over 40% of our sample did not discuss deactivation of the LVAD
device and or pump exchange with their providers and their next-of-kin even though the
majority had their LVAD for almost 2 years. This indicates that less than 50% of the
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participants had discussed their wishes about EOL care with their next-of-kin, who would
be their primary decision maker if they became incapacitated toward the EOL.
The recent Intermacs analysis showed over 75% of LVAD patients die in the
hospital.23 This finding is important because in a large systematic review, researchers
found that dying at home is the primary preference of most patients and an indicator of
better EOL care.24 Shared decision making regarding preferences and plan for EOL care
among patients, next-of-kin, and providers, may increase the possibility for patient
preferences to be honored at the EOL and decrease frustration and confusion that often
occurs for patients with an LVAD and their caregivers.25
We saw no differences between our participants with normal cognition and those
with MCI. In the future, we may need to consider whether a higher threshold for MCI
affects EOL decision making in a larger sample. Further analysis may want to focus on
whether there are specific areas of cognition that are related to EOL decision making,
such as language, abstraction, or memory, which may individually be more impactful
than cognition as a whole. It would also be important to analyze whether depression or
anxiety are associated with these relationships, as people with MCI have higher rates of
depression and anxiety than those without MCI, which may have confounded our
results.15
It is also important to recognize that many of our patients did not want to have an
EOL conversation. As providers and researchers, it is imperative to find ways to integrate
these crucial conversations into standard care, and promote the benefit of decreased
confusion and make the EOL process less stressful. Many national organizations across
the country recognize this need across different populations and created initiatives such
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as The Conversation Project and Caring Connections which aim to inform the general
public about the importance of discussing the EOL with loved ones.26 Through open
conversations between stake-holders in EOL decision-making, painful and confusing
scenarios could be avoided, such as being shocked inappropriately by an implantable
cardioverter defibrillator, or being unaware of the ability to deactivate the LVAD device
in the setting of a terminal illness. The additional layers added to EOL care created by
having a cardiac device necessitate the need and importance of communicating about
EOL scenarios prior to an EOL situation.
In addition to EOL discussions, it is crucial the providers continue to educate
patients and their families regarding the purpose of the LVAD and the limitation of pump
exchanges. In this study, over 25% of the population said they would want a pump
exchange even if they were suffering from another terminal illness such as cancer, and
81% said they would want a pump exchange despite their quality of life not improving
with the first pump. Providers need to ensure patients are aware of the risks that pump
exchange can create, and if scenarios arise what situations might prompt a discussion
related to end-of-life versus a pump exchange surgery. It seems there are many
misconceptions related to when a pump exchange would be an acceptable treatment
option, especially in the setting of another terminal disease besides HF, and with more
guidance and education from providers, these misconceptions could decrease. However,
these notions of persevering, despite life-threatening obstacles, are supported by findings
that although most people say they want higher quality of life, compared to quantity of
life,27 when EOL situations occur, many individuals change their minds and choose life at
all costs.
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Misunderstandings about LVADs and lack of EOL discussions with providers
may also be related to lack of provider knowledge about EOL decision making. Providers
of patients with LVADs also struggle to know what their role is and how to educate
patients and family members about the decision making processes.28 In an analysis of
cardiologists and palliative care physicians who routinely take care of patients with an
LVAD, researchers found that there are several different perspectives among providers,
and that this may lead to increased confusion for patients and their caregivers due to
varying opinions or lack of opinions voiced by the physicians who take care of them.28 In
the future, more emphasis is needed on the role that providers play in informing patients
and families regarding EOL scenarios, and ensure that they have adequate understanding
of how the device functions in various EOL scenarios.
In a recent qualitative study, patients with an LVAD and their caregivers had a
mind set about ‘being saved’ and feeling a moral obligation to continue fighting no
matter the obstacles.29 This sense of moral obligation to continue fighting, and a sense
that this expensive and complex device saved their lives, so patients’ feel a need to
continue fighting and persevering, despite threats of mortality, may be related to patients
not wanting to discuss EOL with their providers, as well as a mentality to continue with
treatments despite life-threatening diagnoses.
Moving forward, more emphasis is needed to ensure patients and their families
have a realistic expectation of life with an LVAD and that EOL discussions are had prior
to implantation and continued throughout care. We also need to ensure that providers are
equipped with the skills and knowledge to discuss EOL decision making throughout the
care continuum of patients with an LVAD. By continuing to research and educate EOL
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decision making, we could prevent confusing, painful, and frustrating situations that may
arise at the EOL for family members and patients with an LVAD.
5.5 Limitations
The sample was from a single-center, thus limiting generalizability. The end-oflife questionnaire was based on hypothetical scenarios which can be problematic for
applicability and generalizability, however, to get data about this type of information,
self-report is the only way. The sample size was small, and may not have been powered
strong enough to conclude there was no differences between groups, however, in the
LVAD literature, 30 LVAD patients is quite large and thus may be an adequate sample
size.
5.6 Conclusions
End-of-life decision making for patients with chronic illness is a complex process,
and adding advanced medical technology to that process can increase complexity.
Approximately half of our population had discussed EOL decisions with their providers
or their next of kin, indicating a large gap in care. Patients who had MCI, which was
around 80% of our sample, did not have different experience and attitudes regarding EOL
decision making. More emphasis needs to be placed on educating patients and their
families about these difficult decisions made at the EOL, as well as educating providers
about ways to discuss EOL scenarios with patients. By improving these conversations
and understanding what may influence EOL decision making, we can hopefully improve
decision making processes for patients with an LVAD and their families when they reach
the EOL.
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Table 5.1 Participant characteristics for the total sample and compared between those with and
without mild cognitive impairment
Full Sample

MoCa Score

MoCa Score

(N=30)

25 and

26-30 (n=6)

P-value

below
(n=23)
60 ± 14

45 ± 19

0.135

23 (76.7)

17 (73.9)

5 (83.3)

0.620

White

27 (90)

20 (87)

6 (100)

0.224

Black or other minority

3 (10)

3 (13)

0 (0)

0.224

Single

7 (23.3)

4 (17.5)

3 (50)

0.141

Married

15 (50)

11 (47.8)

3 (50)

Divorced/Separated/Widowed

8 (267)

8 (34.8)

0 (0)

8 (26.7)

5 (22.7)

2 (33.3)

Age (years)

57 ± 16,
range 21-79

Sex: male, n (%)
Race n (%)

Marital status n (%)

NYHA classification, n (%)
III
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0.603

IV

21 (70)

17 (77.3)

4 (66.7)

1

4 (13.3)

3 (13.6)

1 (16.7)

2

6 (20)

5 (22.7)

1 (16.7)

3

17 (56.7)

12 (54.5)

4 (66.7)

4

2 (6.7)

2 (9.7)

0 (0)

Destination Therapy

19 (63.3)

17 (73.9)

1 (16.7)

Bridge to Transplant

11 (36.7)

6 (26.1)

5 (83.3)

ICD Therapy, n (%)

25 (83.3)

19 (86.4)

5 (83.3)

0.853

Days with LVAD Therapy

702 ± 589,

702 ± 408

408 ± 478

0.218

Intermacs Profile, n (%)
0.754

Indication, n (%)
0.010

range 34 2472
Pump Exchange, n (%)

3 (10)

2 (9.1)

1 (16.7)

0.612

Diabetes, n (%)

14 (46.7)

11 (47.8)

2 (33.3)

0.525

High Blood Pressure, n (%)

16 (53.3)

12 (52.2)

4 (66.7)

0.525

Kidney Failure, n (%)

6 (20)

5 (22.7)

0 (0)

0.198

Lung Problems, n (%)

10 (33.3)

8 (36.4)

2 (33.3)

0.891

86

Stroke, n (%) (n=28)

4 (13.3)

4 (18.2)

0 (0)

0.302

Atrial Fibrillation, n (%) (n=26)

18 (60)

13 (68.4)

4 (66.7)

0.936

History of Myocardial Infarction, n

12 (40)

8 (42.9)

2 (40)

0.907

23 ± 4, range

22 ± 3

28 ± 1

<0.001

22 [18,34]

16

0.030*

(%) (n=27)
MoCA total score

14 - 29
BUN, median [25th,75th]
Pre-implantation (n=28)

19 [17,30.25]

[11.25,21.25]
3 months post-implant (n=27)

19
[15,21]

20
[15.5,24,5]

16

0.253*

[15,19.5]

Creatinine, median [25th,75th]
Pre-implantation (n=28)

1.16
[0.91,1.29]

3 months post-implant (n=27)

1.37
[0.9, 1.75]

1.07

0.307*

[0.89,1.41]

1.2

1.16

1.20

[0.88,1.51]

[0.87,1.58]

[1.06,1.36]

3065

3065

3177

[1131,4347]

[1053,4156]

[1289,6017]

0.795*

NT-ProBNP, median [25th,75th]
Pre-implantation (n=23)

87

0.529*

3 months post-implant (n=25)

677

859

495

[502,1815]

[542,1970]

[368,1916]

31.9

33.3

29.4

[25.0,37.5]

[24.7,38.7]

[24.9,33.6]

30.4

27.3

31.6

[23.7,36.5]

[23.6,37.7]

[25.5,34.1]

0.118*

BMI, median [25th,75th]
Pre-implantation (n=28)

3 months post-implant (n=27)

0.351*

0.871*

Legend: Data are shown as mean±SD, except as noted. BUN- Blood urea nitrogen, ICDImplantable cardioverter defibrillator, LVAD- left ventricular assist device, MoCA- Montreal
cognitive assessment, NT-ProBNP- NT-proB-type Natriuretic peptide, NYHA- New York
Hospital Association Class. All comparisons for normally distributed were conducted using C2
likelihood ratios for nominal and ordinal level variables, independent sample paired t-test for
continuous level variables, and ANOVA for more than two group comparison variables, for
non-normally distributed continuous data a Mann-Whitney U test was conducted as denoted by
*. A p-value of 0.05 was considered significant.
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Table 5.2 End-of-Life Questionnaire responses compared between those with and
without mild cognitive impairment
End-of-Life

Total Sample

MoCa Score

MoCa Score

Questions

(N=29)

25 and below

26-30 (n=6)

P-value

(n=23)
Experiences Domain; n (%)
Q.1 Discussed

20 (69)

15 (65.2)

5 (83.3)

0.372

19 (65.5)

15 (65.2)

4 (66.7)

0.947

17 (58.6)

14 (60.9)

3 (50)

0.632

Pump Exchange
with provider:
yes
Q.2 Discussed
pump exchange
with next-of-kin:
yes
Q. 3 Discussed
what turning off
LVAD involves
with provider:
yes
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Q.4 Discussed

16 (55.2)

13 (56.5)

3 (50)

0.775

23 (79.3)

17 (73.9)

6 (100)

0.075

22 (75.9)

16 (69.6)

6 (100)

0.052

14 (48.3)

10 (43.5)

4 (66.7)

0.308

what turning off
LVAD involves
with next-of-kin:
yes
Q.5 I have
discussed illness
trajectory of my
heart disease
with my
provider: yes
Q.6 I have
discussed illness
trajectory of my
heart disease
with my next-ofkin: yes
Q. 7 I have told
my next-of-kin
my wishes
regarding my
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LVAD at the
end-of-life
Q.8 I have at

1 (3.4)

1 (4.2)

0 (0)

0.492

19 (65.5)

15 (65.2)

4 (66.7)

0.947

9 (31)

8 (34.8)

1 (16.7)

0.372

some point
considered
asking my
provider to turn
off my LVAD
Q.9 I have a
religious faith or
outlook which
helps me manage
my daily life as
an LVAD patient
Q. 10 I often
think about
questions
concerning the
end-of-life
Attitudes Domain; n (%)
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Each question began with the phrase: When should providers raise question of what
turning off the LVAD involves?
Q. 11 I never

13 (44.8)

9 (39.1)

4 (66.7)

0.226

22 (75.9)

19 (82.6)

3 (50)

0.115

15 (51.7)

12 (52.2)

3 (50)

0.924

13 (44.8)

9 (39.1)

4 (66.7)

0.226

wish to have
such a
conversation:
agree
Q.12 I myself
will raise the
question when I
feel the need to:
agree
Q. 13 If I am
suffering from a
disease with a
poor prognosis
other than HF:
agree
Q. 14 Routinely
upon visits to
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my LVAD
provider: agree
Q. 15 Towards

25 (86.2)

21 (91.3)

4 (66.7)

0.153

18 (62.1)

14 (60.9)

4 (66.7)

0.793

the end-of-life,
during the last
days: agree
Q.16 If my
LVAD has a
mechanical
malfunction or
has a clot in it:
agree
Attitudes domain cont. n (%)
Each of the following questions began with the phrase: I want to have a pump
exchange…
Q.17* Even if

21 (80.8)

17 (85)

4 (66.7)

0.340

19 (73.1)

14 (70)

5 (83.3)

0.503

my quality of
life has not
benefitted: yes
Q.18* Even I
am seriously ill
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and suffering
from another
disease: yes
Q. 19* Even if I

15 (57.7)

10 (50)

5 (83.3)

0.130

have reached an
advanced age:
yes
Attitudes domain cont. n (%)
Each of the following questions began with the phrase: When I find myself at the endof-life…
Q.20** I wish

22 (81.5)

20 (90.9)

2 (40)

0.017

11 (45.8)

10 (52.6)

1 (20)

0.178

to decide myself
if the LVAD is
turned off or
not: yes
Q.21^ I want
the doctor to
decide if the
LVAD is turned
off or not
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Q.22**I want

18 (66.7)

3 (50)

0.336

my next-of-kin
to decide if the
LVAD is turned
off or not
Legend: LVAD- left ventricular assist device; MoCA- Montreal Cognitive
Assessment; Samples that were not n=29 denoted by the following: *n=26, **n=27,
^n=24- this is related to patients who chose ‘I cannot take a stand’ and were considered
missing data. All comparisons were conducted using C2 likelihood ratios. A p-value of
0.05 was considered significant.
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CHAPTER SIX. Conclusion
6.1 Background and Purpose
The overall purpose of this dissertation was to examine patients’ attitudes and
experiences related to end-of-life conversations involving their left ventricular assist
device (LVAD) or implantable cardioverter defibrillator (ICD), and factors associated
with end-of-life decision making. The following manuscripts were included in this
dissertation: 1) a secondary data analysis of a national cohort of patients with an ICD in
Sweden to identify factors associated with having a conversation about end-of-life with
their providers, 2) an integrative review of the literature focused on end-of-life with an
LVAD from the various stakeholders involved in end-of-life processes, 3) an evaluation
of the psychometric properties of the Control Attitudes Scale-Revised (CAS-R) in
secondary data analysis of patients with an LVAD, and lastly 4) a cross-sectional
correlational study examining experiences and attitudes related to end-of-life and the
relationship of cognition in patients with an LVAD.
With heart disease being the leading cause of death in the United States, end-oflife decision making is crucial for those affected by cardiac disease.1 To treat the high
rates of mortality, cardiac devices have become common, with close to 1.8 million
Americans having either an LVAD or ICD.2,3 However, despite the increased use of these
devices, healthcare providers have done a poor job of informing patients about the
involvement of these devices at the end-of-life. Results from numerous studies
demonstrate patients with an ICD experience inappropriate shocks towards the end-oflife, even in the minutes before death, leading to unnecessary pain and suffering.4-6
Patients with an LVAD, and their caregivers, experience frustration and confusion at the
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end-of-life due to a lack of planning and discussion related to end-of-life care, and in
particular how to integrate the LVAD into end-of-life plans.7,8
The purpose of this chapter is to summarize and synthesize the findings of the
manuscripts presented in this dissertation. It will examine how the outcomes of these
findings will impact and further the state of the science regarding end-of-life decision
making in patients with a cardiac device. Lastly, it will recommend changes regarding
practice and recommendations for research related to end-of-life care and decision
making in cardiac populations.
6.2 Summary of Findings
Chapter Two is a secondary data analysis of a national cohort study of Swedish
patients with an ICD, with and without heart failure, comparing end-of-life attitudes,
experiences, knowledge, and factors associated with having a discussion about ICD
deactivation with a healthcare provider. This study included 3,067 people with an ICD,
and 1,461 (47%) stated they had heart failure. Despite our hypothesis that participants
with HF would have a more comprehensive understanding of end-of-life due to their
higher risk of mortality, we found no differences between the cohorts in their responses
to the end-of-life with an ICD questionnaire. Subsequently, we conducted a hierarchal
logistic regression analysis to identify independent predictors of having a discussion with
their healthcare provider regarding end-of-life scenarios. In the final model, the
significant predictors were having high level of ICD concerns, having had an ICD shock
in the past, and having a high level of anxiety (p<0.001). In this analysis, we found that
our cohort had consistent results with other studies which have demonstrated patients are
reluctant to have end-of-life conversations with their providers,9-11 with over 40% of our
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participants stating they never wished to have an end-of-life discussion with their
providers. These findings suggest more research is needed to assess willingness to
participate in end-of-life discussions and evaluate the best ways to incorporate shareddecision making into end-of-life decision making in patients with an ICD.
Chapter Three is an integrative systematic review of the literature on the current
evidence related to the process and content of end-of-life discussions with an LVAD and
end of life discussion experiences of individuals, families, and healthcare providers of
patients with an LVAD. Overall, there was very little evidence regarding decision making
and end-of-life processes with an LVAD; only six articles were included in this review.
Patients with an LVAD and their caregivers expressed frustration and confusion related
to end-of-life processes associated with dying with an LVAD, and many stated they felt
completely unprepared for the decisions they would have to make towards the end-oflife. The opinions of healthcare providers of patients with an LVAD suggested that there
is controversy related to the ethical permissibility of deactivation of the LVAD, as well as
a divide regarding practices at the end-of-life for patients with an LVAD. The evidence
suggests more research is needed to understand the current healthcare practices related to
end-of-life care for patients with an LVAD, as well as increased education for providers
about end-of-life processes and the ethics surrounding deactivation of the LVAD in order
to develop a consensus about these topics.
Chapter Four is an evaluation of the validity and reliability of the CAS-R in a
cohort of patients with an LVAD. This was a secondary analysis of a longitudinal study
of 89 patients with an LVAD. Cronbach’s alpha in this examination was 0.867 indicating
adequate internal consistency of the CAS-R instrument. Corrected item-total correlations
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were all greater than 0.4 and less than 0.8, indicating homogeneity of responses and lack
of redundancy among the items in the instrument. To examine convergent validity,
hypothesis testing was used. We confirmed associations between lower depressive
symptoms and lower anxiety symptoms, and higher levels of perceived control,
correlating with other studies that have demonstrated prior relationships among these
concepts.12 Overall, the results of this psychometric evaluation support the use of the
CAS-R in the LVAD population, and can be utilized to in future studies as a target for
interventions which aim to improve decision making processes for patients.
Chapter Five is a primary data analysis of a cross-sectional, correlational study of
30 patients with an LVAD, examining end-of-life attitudes and experiences and the
impact of cognition on these processes. Of the 29 participants able to complete cognitive
testing, 23 (79%) had scores indicative of mild cognitive impairment (MCI). There were
no differences in the attitudes or experiences related to end-of-life between the
participants who had MCI and those with normal cognition. Overall, 41% of the cohort
had never discussed end-of-life with their provider, and 30% had never discussed what an
LVAD pump exchange would involve. Forty four percent of the participants said they
never wanted to have a discussion with their provider regarding end-of-life situations
involving their LVAD. There were also several alarming attitudes regarding LVAD pump
exchanges, with 73% saying they would want to have a pump exchange even if they were
seriously ill and suffering from a terminal disease other than heart failure. Despite
patients with MCI having higher mortality rates in the heart failure population,13 those
with cognitive impairment in this study had similar end-of-life attitudes and experiences.
There are several alarming attitudes and experiences related to decision-making at the
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end-of-life and pump exchanges in the LVAD population and future research should
continue to focus on identifying factors associated with these processes.
6.3 Impact of Dissertation on the State of the Science
Despite the increasing prevalence of cardiac devices to treat cardiac disease,
especially end-stage heart failure,3 there is still a gap in that providers are not fully
preparing patients for end-of-life scenarios they may face with a device in place. In
patients with an ICD, it is common for patients to be shocked inappropriately toward the
end-of-life.6 Further, despite recommendations from providers about device deactivation
and the role of the ICD at the end-of-life, many patients are still reluctant to deactivate
their device,10,11 and do not include information about the device in their advanced
directives.9,14 In patients with an LVAD and their caregivers, frustration and confusion is
the overarching theme related to end-of-life care and discussions.7,8 This is further
compounded by the fact that among providers of patients with an LVAD, there is a lack
of consensus on how to handle end-of-life scenarios and questions of ethical
permissibility of deactivation of the device.15,16 In both cohorts of patients, there is a lack
of guidance from professional organizations about topics that need to be addressed endof-life scenarios, and scenarios in which it is acceptable to deactivate a device.17-19
Through this dissertation, I have advanced the state of the science of end-of-life
decision making in patients with a cardiac device by: 1) identifying factors related to
having a discussion with your provider in regards to deactivation of an ICD, 2)
identifying overarching themes related to end-of-life opinions and experiences of the
shareholders involved in end-of-life decision-making processes, 3) identified an
appropriate measure of perceived control in the LVAD population, which could be a
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target in future interventions related to end-of-life decision making, 4) and described
experiences and attitudes related to end-of-life discussions related to deactivation and
pump exchange in a cohort of patients with an LVAD.
In a large cohort of ICD patients I identified factors that were significantly
associated with having a discussion with their provider regarding end-of-life.
Understanding that end of life discussions are predicted by having an ICD shock, having
a high level of concerns related to the ICD, and high levels of anxiety can help identify
individuals in larger populations who may be more willing to have end-of-life
discussions. I also established that there are large segments of the population who never
want to have end-of-life discussions, and isolated a new group of people who may need
more innovative and targeted ways to educate and involve them in end-of-life decisionmaking and care planning.
Next, in the integrative review of end-of-life experiences and processes for
providers, families, and patients with an LVAD, I identified a dearth of research in the
area. The six articles that were identified, illuminated that patients and caregivers are
unprepared to make the necessary decisions regarding deactivation at the end-of-life, and
are left frustrated and confused at these times. Providers in multiple fields, including
cardiology, palliative medicine, and cardiothoracic surgery, all have differing opinions on
how to handle end-of-life scenarios for patients with an LVAD, and are unsure of the
ethical permissibility of deactivation. This limited evidence highlights the need to
develop a more comprehensive understanding of what patients are being told about endof-life with an LVAD, and how providers’ opinions are related to when these discussions
occur. This review of the literature provided the foundation for the cross-sectional study
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related to end-of-life experiences and attitudes for patients with an LVAD reported in
Chapter Five.
In order to ensure there was an adequate measure of perceived control in the
LVAD population, the findings in Chapter Four established that using the CAS-R in the
LVAD population is a valid and reliable measurement of perceived control. This could
aide future studies to identify the role perceived control plays in end-of-life decisionmaking and is also a modifiable trait that could be targeted in interventions to promote
informed decision-making.
Findings in Chapter Five were the first exploration and description of end-of-life
attitudes and experiences related to end-of-life deactivation and pump exchange of
patients with an LVAD. These findings demonstrated, similar to those found in the ICD
study, that there are significant portions of the population who have never discussed any
scenarios related to end-of-life with their providers. There are also a large percentage of
the population, despite the high risks associated with living with an LVAD, who would
choose to never have a conversation related to end-of-life decision making. Unlike in the
ICD study, we were unable to isolate specific factors that predicted having an end-of-life
discussion with their provider or next-of-kin regarding end-of-life, and further research is
needed to continue to understand these phenomena.
Finally, through all the findings from this dissertation, I am beginning to assemble
the foundations of a conceptual model aimed at identifying factors associated with endof-life decision making for patients with a cardiac device. By beginning to identify
specific factors such as ICD shock history, and high levels of concern and anxiety,
identified in the ICD study, we can see that there are certain predictors associated with
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higher rates of end-of-life discussions. Through the integrative review, we can see that
lack of education and guidance to patients, families, and providers result in disjointed and
poor end-of-life setting for all shareholders involved. By having a validated tool to
measure a possible factor involved in end-of-life decision making, as seen in the CAS-R
testing, we can begin to test perceived control as a possible target in end-of-life decision
making framework. And lastly, by examining the experiences and attitudes related to
end-of-life decision-making in the LVAD population, we can start to analyze various
factors that this unique population all needs addressed in their decision-making process.
Also, in the LVAD end-of-life study, we aimed to identify the role that cognition may
play in end-of-life decision making, and while in this study, it did not impact decisionmaking, more research in the future is needed to clearly identify the role that cognition
plays in these complicated processes. Through these studies, an outline of a framework
can begin to be deciphered and more thoroughly tested in the future.
6.4 Recommendations for Practice and Research
End-of-life decision making is an over-looked component of care for patients with
a cardiac device. In multiple studies, evidence has shown that patients with cardiac
devices are not informed about the decisions that should be made prior to end-of-life
scenarios, which could ultimately end up harming the patient. Future studies should
continue to examine the experiences of patients and their families regarding the
experiences related to end-of-life situations they are experiencing, especially in the
LVAD community. I hope to continue the study described in Chapter Five at other
institutions to identify if there are similar themes observed when other care-providers are
involved.
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Another large gap in the current literature and practice is what providers are being
taught and what are they experiencing when trying to discuss end-of-life scenarios with
their patients. In two populations of patients who have cardiac devices, and both
demonstrated that 40% had never discussed end-of-life scenarios with their providers. It
is critical to understand what may deter providers from discussing end-of-life with certain
patients, or if there is a disconnect where providers feel they have discussed a concept
adequately, but in fact the patient does not feel the issue has been discussed. In discussing
this phenomenon with another LVAD researcher, Colleen McIlvennan, DNP, RN, she
also agrees that more research is needed on provider education about end-of-life
discussions, and she is currently in the grant-submission process on a study within this
area.
Additional studies are also needed in the area related to reaching people who do
not want to discuss end-of-life decision making. In both the LVAD and ICD study,
around 40% said they never wished to have a discussion with their provider regarding
deactivation or end-of-life. It would prudent to qualitatively evaluate these types of
patients to see what their concerns related to this topic are and how healthcare providers
and researchers can more adequately meet their needs, increase their comfort surrounding
these types of conversations, and ensure they have the tools they need to make decisions
for end-of-life care.
Last, over the course of my career I hope to continue to build on the conceptual
model around decision-making at the end-of-life. By continuing to identify factors
involved in these processes, we can begin to target interventions aimed at improving
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patient, family, and provider participant in this extremely complicated decision-making
process.
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